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GABA is the main inhibitory neurotransmitter of the central nervous system (CNS). Recently, 
GABAergic transmission has been reported to be depolarizing and possibly excitatory rather than 
inhibitory in a number of neurodevelopmental disorders both in patients and mouse models.  
In particular, the Ts65Dn mouse model of Down syndrome (DS) exhibits depolarizing GABA due to 
upregulation of the Cl- importer NKCC1 both in the hippocampus and in the cortex. Moreover, 
NKCC1 inhibition by the FDA-approved diuretic bumetanide is able to rescue inhibitory GABAergic 
transmission, synaptic plasticity and cognitive functions in Ts65Dn mice.  
Beside cognitive impairment, DS mice and people with DS show sleep disturbaces. Since sleep 
pattern is regulated by GABAergc transmission, we reasoned that the alteration of GABAergic 
transmission due to upregulation of NKCC1 might be underlying at least some of the sleep 
disturbances in DS mice. So, we characterized sleep in Ts65Dn mice and investigated the effects of 
a chronic treatment with bumetanide. We found that bumetanide ameliorates the quality of sleep 
in NREM and REM sleep phases before and after sleep deprivation and decreases abnormal 
wakefulness during light phase at baseline in Ts65Dn mice. Moreover, we also found abnormalities 
in other parameters, which could contribute to sleep abnormalities of Ts65Dn mice: an increase of 
food intake and activity (partially rescued by bumetanide) with a reduction of body temperature 
during dark phase. 
Because of the association of altered GABAergic signaling by dysregulation of the expression of 
NKCC1 (but also of the Cl- exporter KCC2) in many neurodevelopmental disorders characterized by 
cognitive or social impairment, and sleep disorders, we extended our studies to Prader Willi 
syndrome (PWS). PWS is a neurodevelopmental disorder, caused by defects of genomic imprinting 
and characterized by cognitive, social and sleep abnormalities. Here, we observed that the Snord116 
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mutant mouse model of PWS, PWScrm+/p− show an increased expression of NKCC1, specifically in the 
hippocampus in comparison to their wild-type mice. Moreover, we report that PWS mice have 
altered cognition and the circadian period in free-running conditions. In particular, mutant mice 
present defects of long-term memory and a reduced shortening of their circadian period together 
with an increase of alpha activity in dark-dark (DD). Moreover, they also show alteration of pain 
sensitivity, that could be linked to defects in the thermoregulation. Interestingly, in constrast with 
PWS people, Snord116 mutant mice showed no alterations of anxiety, repetivive, obsessive and 
social behaviors.  
In an effort to rescue cognition and the circadian phenotype by rescuing NKCC1 inhibition, we 
treated Snord116 mutant mice with bumetanide. Remarkably, bumetanide treatment resulted in a 
complete rescue of the cognitive defects and circadian alteration in DD, with no effects in controls. 
Our results suggest an important link between GABA transmission and the regulation of cognition 
and the circadian clock in PWS.  In addition, the current study extends the repertoire of disorders in 
which NKCC1 inhibition attenuates behavioural deficits and proposes a new potential mechanism 
















1. Neurodevelopmental Diseases 
Development and maturation of the nervous system are the result of a biological process known as 
“neurodevelopment”. In humans, this process arises during the third week of embryonic growth, 
characterized by the formation of the neural tube (Bishop KM et al, 2002; Sur M et al 2005; Stiles J 
et al, 2010; Tau GZ and Peterson BS, 2010; Stiles J, 2011). Afterwards, starting from the ninth week 
onward, a gradual process of maturation takes place in the brain, allowing its typical structure 
acquisition. Several events are involved under a tight organization, such as a large cell proliferation, 
migration, and differentiation (Stiles J et al, 2010; Tau GZ et al, 2010; Stiles J, 2011) (Fig1).  
   
 
    





Any alteration or interference on these ordered and complex processes may result in aberrant brain 
development and give rise to the onset of a neurodevelopmental phenotype, where falls the 
definition of neurodevelopmental disorders (NDDs) (Moreno-De-Luca A, et al 2013; Mullin AP et al, 
2013; Platzer K, et al, 2019). 
Neurodevelopmental disorders are alterations that spring during childhood. These disorders 
comprise a wide variety of diseases (e.g., Down syndrome, autism spectrum disorders, Prader Willi 
syndrome). Nevertheless, there are a number of common symptoms that these diverse diseases 
share. These include abnormal brain development, cognitive defects, language disorders, sleep 
disturbances, circadian rhythms alterations, psychopathologies (e.g. anxiety), and increased 
susceptibility to seizures (Soni S et al, 2008; Mullin AP et al, 2013; Viggiano et al, 2015; Robinson-
Shelton A and Malow BA, 2016; Thomas S et al, 2017; Diamandopoulos and Green 2018; Niemi MEK 
et al, 2018; Carmassi et al, 2019). 
Currently, the high incidence rate of these diseases is a serious issue for the national health systems 
of various countries, affected individuals and their families. Recent reviews in various populations 
showed an average global estimate of 62/10,000 for autism (Elsabbagh M et al, 2012) , 10.37/1000 
for intellectual disability (Maulik PK et al, 2011), 1/1000 for DS (Weijerman, ME and de Winter JP, 
2010) 1/15,000–1/20,000 for PWS (Soni S et al, 2008), and a prevalence of median lifetime around 
4/1000 for schizophrenia (Welham J et al, 2008). Manifold possible causes have been correlated 
with NDDs; those include genetic factors, environmental conditions, infectious and traumatic 
events. Interestingly, these factors show a significant interaction between each other, highlighting 
the impact of their reciprocal influence (Moreno-De-Luca A, et al 2013). As matter of fact, the co-
occurrence of different NDDs has been often demonstrated in the literature (e.g. Singh T et al, 2017), 
possibly indicating the presence of common biological/cellular mechanisms (Gilman SR et al, 2011; 
Kilinc M et al, 2018). 
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The genetic mechanisms underlying NDDs are far from being understood, although much progress 
has been made in this filed in recent years. Mutations in several hundred genes, known to be 
associated with neurodevelopmental pathways, such as chromatin remodeling, synaptic function 
and transcriptional regulation genes have been associated to a wide spectrum of NDDs (Darnell 
Jennifer C, et al 2011; De Rubeis S et al, 2014; Iossifov I et al, 2014). Interestingly there is a marked 
overlap of these genes results across the diverse NDDs, further strengthening the idea of a possible 
presence of common biological/cellular mechanisms. Among studies on genetic mechanisms 
implicated in the NDDs, investigation on the epigenetic mechanisms are also gaining a significant 
importance (Kubota T et al, 2013). Epigenetic mechanisms are fundamental to determine 
physiological development during embryogenesis and a proper differentiation of neural cells (Li E et 
al, 1993; Takizawa T et al, 2011). These epigenetic mechanisms comprise DNA methylation and 
histone modification and have been implicated in different congenital disorders affected by 
problems of genomic imprinting. (Payer et al, 2011; Kubota T et al, 2013). In particular, genomic 
imprinting refers to a type of epigenetic mechanism, where transcriptional mechanisms of 
regulation are strictly regulated in a parent of origin manner. During gametogenesis imprinted 
regions of DNA are specifically marked through methylation, determining a parent-specific 
expression (Mac Donald, 2012). Interestingly, mutations or alterations of these regions may be 
implicated in the onset of NDDs, as happens in PWS or AS (Kubota T et al, 1997). Moreover, large 
evidence has shown how different environmental factors such as a poor nutrition, use of drugs, and 
mental stress, may cause alterations on the epigenetic gene regulation in the brain, thus impacting 
brain function (Jirtle Rl, et al, 2007; Alegria-Torres et al, 2011). Interestingly, epigenetic mechanisms 
are reversible mechanisms, which involves modifications of factors binding on and detachment from 
DNA and histone proteins. Hence, the exploitation of epigenetic reversibility based on the 
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rearrangement of abnormal epigenomic patterns may be potentially helpful for therapies for NDDs 
(Handy D E et al, 2011).  
In recent years, a lot of NDDs have been also associated to dysfunction of inhibitory GABAergic 
transmission (Ben-Ari 2017). In particular, experiments carried out on both animal models and 
postmortem human samples have demonstrated an excitation/inhibition imbalance in neuronal 
circuits linked to neurodevelopmental defects in GABAergic transmission common to many 
neurodevelopmental disorders including DS (Deidda et al, 2015) and PWS (Lucignani G et al, 2004; 
Ebert MH et al, 1997; Rice L J et al, 2016). Interestingly, some of the symptoms common to all NDDs 
(i.e., increased susceptibility to seizures, cognitive impairment, sleep disorders) have been 
previously associated to impairment in GABAergic transmission (Plante David T et al, 2012; Ben-Ari 
et al, 2017). In this thesis, I investigated the contribution of impaired GABAergic transmission to 
sleep disorders in DS mice and cognitive impairment of PWS mice.  
 
2. GABA and Cl- homeostasis  
 
Gamma-aminobutyric acid (GABA) is the main inhibitory neurotransmitter in the central nervous 
system. GABA plays an important role as regulator of neuronal networks during mammalian 
ontogenesis. In particular, neuronal development is orchestrated by GABAergic signaling in terms 
of neural proliferation, migration, differentiation, and neuronal-network wiring. In the adulthood, 
the neurotransmitter GABA regulates the activity of different neuronal cell-types widely 
interconnected, by strongly modulating synaptic activity. GABA exerts these functions by binding to 
chloride-permeable ionotropic GABAA receptors and metabotropic GABAB receptors (Deidda et al, 
2014). Synaptic currents induced when GABA binds to GABAA receptors are carried by chloride (Cl−) 
and, to a lesser degree, by bicarbonate (HCO3−). GABAA receptor-mediated conductance either 
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hyperpolarize or depolarize a neuron depending on its internal Cl− and HCO3− concentrations and 
membrane potential. Two cation-chloride cotransporters are fundamental in controlling neuronal 
Cl− (Payne JA et al, 2003; Sipila ST et al, 2006): the Na-K-2Cl cotransporter NKCC1, which imports Cl− 
in the neurons and promotes depolarizing responses to GABA, and the K-Cl cotransporter KCC2, 
which releases Cl− outside of the cell, supporting hyperpolarizing responses. Expression and function 
of both transporters are controlled at multiple levels.  
During development, KCC2 expression is upregulated, while NKCC1 is downregulated (Yin D et al, 
1996; Plotkin MD et al, 1997; Rivera C et al, 2004; Dzhala VI et al, 2005). These changes are 
associated with a hyperpolarizing shift in the reversal potential of GABAergic responses (Ben-Ari et 
al, 1989; Payne JA et al, 2003; Farrant M et al, 2007). Thus, under physiological conditions, adult 
neurons present reduced intracellular Cl- concentration [(Cl-)i] underlying the GABAergic inhibitory 
drive (Fig.2).  
 
 
             




In contrast, neurons have high [(Cl-)i] levels with depolarizing and possibly excitatory GABA actions 
in a large range of pathological conditions such as Down, Autism and Rett syndromes, spinal cord 
lesions, chronic pain, brain trauma, cerebrovascular infarcts, and, different types of epilepsies, and 
other genetic or environmentally-related conditions. Interestingly, of the NKCC1-inibitor 
bumetanide efficiently restores reduced [(Cl-)i] levels, GABAergic transmission in mouse models of 
these disorders. Most notably, bumetanide can also rescue core behavioral symptoms in mice and 
some clinical trials patient case studies (Ben-Ari, 2017). 
 




Epilepsy is a neurological disorder characterized by epileptic seizures. These are caused by altered, 
excessive or hypersynchronous neuronal activity in the brain (Chang & Lowenstein, 2003). Several 
pieces of evidence suggest that neuronal hyperexcitability and hypersynchronization are the result 
of an alteration of the delicate balance between excitatory and inhibitory synaptic activity. 
Interestingly, an imbalance in NKCC1 and KCC2 activity together with depolarizing GABAergic action 
have been observed in several animal models of epilepsy (Ben-Ari, 2017; Di Cristo et al., 2018). The 
first lines of evidence about the involvement of the two cation chloride cotransporters (CCCs) in 
epileptogenic activity came from the late 90s, when four independent studies found that the 
antagonization of NKCC1 with furosemide or bumetanide caused a block of epileptic activity both in 
vitro and in vivo in rats (Hochman et al., 1995; Hochman et al., 1999; Hochman & Schwartzkroin, 
2000; Schwartzkroin et al., 1998). In 2002, four other works demonstrated the direct relationship 
between NKCC1, KCC2 and epileptic pathogenesis. In particular, high NKCC1 expression was 
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indicated as a factor influencing the increased susceptibility to seizures in the developing brain. In 
this study, bumetanide administration was able to rescue epileptiform activity both in vitro and in 
vivo during development in rodents (Dzhala et al., 2005). Moreover, increased expression of NKCC1 
was found in the amygdala-kindling model of seizures in rats (Okabe et al., 2002). Furthermore, a 
decrease in KCC2 expression was found in the mouse hippocampus after kindling-induced seizures 
(Rivera et al., 2002). Finally, mice deficient in KCC2 showed frequent seizures. This may be possibly 
due to a shift in the ECl, which leads to impaired efficacy of GABAAR-mediated inhibition and/or to 
less reuptake of potassium and chloride during high-frequency spikes (Woo et al., 2002). Stemming 
from these first works, several other studies in rodent models confirmed the involvement of an 
altered NKCC1/KCC2 ratio in the pathogenesis of epilepsy. A number of these studies also confirmed 
positive outcomes upon bumetanide treatment (Almeida et al., 2011; Amadeo et al., 2018; Baek et 
al., 2016; Cleary et al., 2013; Dzhala et al., 2008; Dzhala et al., 2010; D. A. Edwards et al., 2010; 
Eftekhari, Mehrabi, et al., 2014; Hu et al., 2017; Kelley et al., 2018; Koyama et al., 2012; X. Li et al., 
2008; Loscher et al., 2013; MacKenzie & Maguire, 2015; MacKenzie et al., 2016; Marguet et al., 
2015; Mazarati et al., 2009; Nardou et al., 2009; Reid et al., 2013; Robel et al., 2015; Santos et al., 
2017; Sivakumaran & Maguire, 2016; Tao et al., 2016; Tollner, F. Wang et al., 2017; J. Zhang et al., 
2016). 
Interestingly, an imbalance in the NKCC1/KCC2 ratio is also present in human patients. First, 
upregulation of NKCC1 and/or downregulation of KCC2 was found in the hippocampal subiculum 
and hippocampi obtained from patients affected by temporal lobe epilepsy (Huberfeld et al., 2015; 
Huberfeld et al., 2007; Munoz et al., 2007; Palma et al., 2006; Sen et al., 2007).  Then, other studies 
found altered expression of NKCC1 and/or KCC2 in the cortical malformation of patients affected by 
medically intractable epilepsy (Aronica et al., 2007; Sen et al., 2007; Shimizu-Okabe et al., 2011) in 
hypothalamic hamartoma, a rare epileptogenic lesion associated with gelastic seizures (D. Y. Kim et 
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al., 2008), in cortical samples from epileptic children (Jansen et al., 2010), and in peritumoral tissues 
with high seizure susceptibility (Conti et al., 2011; Pallud et al., 2014). Notably, an increased 
expression of NKCC1 and a decreased expression of KCC2 were observed also in brain samples 
obtained from patients affected by Dravet syndrome, an infantile encephalopathy characterized by 
severe epilepsy and cognitive impairment (Ruffolo et al., 2018). Interestingly, bumetanide 
treatment ameliorated seizure frequency in temporal lobe epilepsy (Eftekhari, Mehrabi, et al., 
2014). Moreover, bumetanide was able to reduce seizure duration and frequency in a child affected 
by intractable multifocal seizures (Kahle et al., 2009). Nevertheless, the NEMO trial, assessing the 
efficacy and safety of the use of bumetanide for the treatment of acute neonatal encephalopathy 
seizures (Pressler et al., 2015), was recently interrupted due to poor bumetanide antiepileptic action 
and ototoxicity (Ben-Ari et al., 2016). Moreover, the involvement of KCC2 in the pathogenesis of 
epilepsy has been recently questioned based on conflicting results showing increased KCC2 
expression in epileptic brain tissue from both human (Jansen et al., 2010; Karlocai et al., 2016) and 
rodent models (Awad et al., 2016; Galanopoulou, 2008; Khirug et al., 2010). Nevertheless, the 
conflicting results showed both decreased and increased KCC2 expression in epilepsy; this 
discrepancy could depend on brain region, stage of disease, gender, or the influence of seizures 
themselves. Indeed, KCC2 activity causes potassium elevation in the extracellular compartment, 
which could contribute to the lowering of the threshold for the generation of the seizures and to 
the synchronization of the epileptiform discharges (Di Cristo et al., 2018). Thus, although the 
involvement of alterations of NKCC1 and KCC2 expression/activation in epilepsy is clearly 
demonstrated, deeper studies to better investigate their delicate modulation and assess the 





3.2 Autism spectrum disorder (ASD) 
 
Autism spectrum disorder (ASD) is a group of syndromes characterized by different etiologies, but 
common core symptoms (e.g., repetitive behaviors, deficits in social interaction and language 
impairment; (Pizzarelli & Cherubini, 2011), suggesting that possibly there are common mechanisms 
underlying ASD pathology. Moreover, ASD can be comorbid with other neurodevelopmental 
syndromes such as epilepsy (M.L. Lewis et al, 2018), Rett syndrome (Percy, 2011), Fragile X 
syndrome (Kaufmann et al, 2017), or Down syndrome (J. Moss et al, 2013). Several pieces of 
evidence, both from rodent models and humans, indicate that commonly altered GABAergic 
transmission could underlie ASD pathology (Cellot & Cherubini, 2014). In particular, the pioneering 
observation of a paradoxical effect upon the administration of GABAA signaling enhancing 
benzodiazepine diazepam in autistic children (e.g., anxiety and aggression (Marrosu et al, 1987), 
suggested the possibility of depolarizing GABA action in ASD. This idea prompted researchers to test 
whether the inhibition of NKCC1 by bumetanide could be a valid therapeutic strategy in five autistic 
children (Lemonnier & Ben-Ari, 2010). The amelioration of some behavioral aspect related to ASD 
upon bumetanide treatment opened the way for a larger clinical trial designed for 54 autistic 
patients (Lemonnier et al., 2012) and consequently a phase II clinical study (Lemonnier et al., 2017). 
These studies confirmed that bumetanide is able to ameliorate the core symptoms of ASD measured 
by the Childhood Autism Rating Scale (CARS). Moreover, bumetanide resulted efficient in the 
treatment of a young girl with Asperger syndrome, a neurodevelopmental disorder belonging to 
ASD (Grandgeorge et al., 2014). In parallel to the clinical studies, KCC2 expression was 
downregulated in the VPA rat model of ASD. Interestingly, bumetanide administration in VPA-
treated pregnant rats resulted in the rescue of core behaviors related to ASD in their offspring 
(Eftekhari, Shahrokhi, et al., 2014; Tyzio et al., 2014). Nevertheless, the lack of preclinical studies 
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addressing bumetanide treatment at the developmental stages comparable to those of patients 
enrolled in clinical trials and the paucity of mouse models of autism tested among the many that 
exist, highlights the need for further investigation. 
 
3.3 Fragile X syndrome (FRX) 
 
Fragile X syndrome (FRX) is a genetic disorder caused by mutations in the X-linked FMR1 gene 
encoding for Fragile X mental retardation protein (FMRP). FMRP is a regulator of the translation of 
several mRNAs. FXS individuals show cognitive deficits, autistic behavior, hypersensitivity to sensory 
stimuli and comorbidity with epilepsy (Morel et al., 2018). These symptoms led researchers to 
hypothesize an excitatory/inhibitory imbalance, as previously observed in ASD and epilepsy. In 
particular, driven by the positive outcome of the earlier pilot study on autistic patients (Lemonnier 
et al., 2012), the same authors treated a FXS child with bumetanide. Interestingly, bumetanide 
administration resulted in the amelioration of the score of each of the 5 clinical tests performed to 
probe autistic core symptoms (Lemonnier et al., 2013), opening the route to larger clinical trials. In 
agreement with the clinical study, FXS mice showed a delay in the developmental switch of GABA 
polarity from depolarizing to hyperpolarizing, due to increased expression of NKCC1 (He et al., 
2014). The same year, Tyzio and colleagues found increased Cl- concentrations in hippocampal slices 
from FXS mice at P15 and P30 due to a decreased level of KCC2. Fetal treatment with bumetanide 
right before birth was able to recover the intracellular Cl- concentration, GABAergic transmission 
and the behavioral features related to autism later in life (Eftekhari, Shahrokhi, et al., 2014; Tyzio et 
al., 2014). Recently, treatment of FXS mice with bumetanide during the critical period of 
somatosensory cortex plasticity rectified GABA polarity and synaptic plasticity and allowed long-
lasting restoration of proper somatosensory-circuit formation (He et al., 2018). Moreover, a recent 
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study found that bumetanide treatment by itself was insufficient to completely rescue social 
impairment in the automated tube test in FXS mice, suggesting the need for a combination therapy. 
Nevertheless, in the same study, the combination of the genetic reduction of mGluR5 expression 
together with bumetanide treatment worsened social impairment, indicating that the combination 
therapy needs to be better investigated in terms of drug type, targeting pathway and time window 
of administration (Zeidler et al, 2017). Although there are only a few studies in animal models and 
in humans, the abovementioned evidence confirms the involvement of the NKCC1/KCC2 imbalance 
in the pathogenesis of FXS syndrome and their modulation as a possible therapeutic strategy. 
 
3.4 Rett Syndrome (RTT) 
 
Rett syndrome (RTT) is a neurodevelopmental disorder caused by mutations in the X-linked Methyl-
CpG-binding protein (MECP2) gene. Mecp2 binds to methylated DNA and regulates the transcription 
of a large number of genes. Individuals affected by RTT grow normally until the age of 6-18 months, 
but then develop various symptoms (e.g., cognitive impairment, seizures, altered motor function 
and stereotyped behaviors; (Ehinger et al., 2018). As for autism, several pieces of evidence indicate 
a possible alteration in the GABAergic signaling in RTT rodent models and humans (Cellot & 
Cherubini, 2014). The first evidence regarding alterations in the NKCC1/KCC2 balance came from a 
study of corticospinal fluid (CSF) obtained from RTT patients, where a decreased level of KCC2 
expression was found (Duarte et al., 2013). More recently, deficits in KCC2 expression have been 
found in human RTT patient stem cell-derived neurons (Tang et al., 2016) and in a mouse model of 
RTT (Banerjee et al., 2016). Interestingly, Insulin-like Growth Factor-1 (IGF1) treatment ameliorated 
the severity of the syndrome  both in RTT mouse models (Castro et al., 2014; Tropea et al., 2009) 
and in  RTT patients (Khwaja et al., 2014; Pini et al., 2016), thus suggesting its implementation in the 
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treatment of NDs (Bou Khalil, 2017). Moreover, the pharmacological enhancement of KCC2 gene 
expression is able to exert therapeutic effects on human Rett syndrome neurons. Indeed, it rescues 
the electrophysiological and morphological abnormalities of these neurons. In addition, 
enhancement of KCC2 expression is able to ameliorate disease-related breathing pauses and 
locomotion deficits in Mecp2 mutant mouse model of RTT (Mecp2 −/y) (Tang X at al, 2019). 
Nevertheless, further investigation of the NKCC1/KCC2 ratio and its consequence on GABA signaling 
are needed to better clarify the role of CCCs in the pathogenesis of RTT and their possible 




 Schizophrenia is a neurodevelopmental disorder characterized by psychosis and cognitive 
impairments, leading to disability and premature mortality. In particular, the clinical manifestations 
can be divided into three categories: positive symptoms (e.g., hallucinations), negative symptoms 
(e.g., depression and apathy) and cognitive symptoms (D.A. Lewis, 2012). The etiology of 
schizophrenia is still under investigation, but a large body of literature agrees on the contribution of 
both genetic and environmental factors. GABAergic transmission seems again to play an important 
role in the pathogenesis of this ND (Balu & Coyle, 2011). In particular, the first pieces of evidence of 
impaired Cl- homeostasis in schizophrenia came from a study on the prefrontal cortex (and later the 
hippocampus) of schizophrenic patients, where NKCC1 expression was increased (Dean et al., 2007; 
Hyde et al., 2011). A few years later, alterations in SLC12A2 and SLC12A5 genes, encoding for NKCC1 
and KCC2, respectively, were indicated as susceptibility genes for schizophrenia development in 
patients (J.Y. Kim et al., 2012; Merner et al., 2015; Merner et al., 2016; Potkin et al., 2009). 
Furthermore, increased expression of two kinases regulating NKCC1 and KCC2 activity, OXSR1 and 
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WNK3, was found in the prefrontal cortex of schizophrenic subjects, indicating a possible increase 
in NKCC1 activity and a decrease in KCC2 function in schizophrenic patients (Arion & Lewis, 2011). 
In addition, an altered NKCC1/KCC2 ratio was described in two different mouse models of 
schizophrenia (Larimore et al., 2017; Yang et al., 2015). Finally, an interplay between NKCC1 and the 
protein Disrupted in schizophrenia 1 (DISC1, an intrinsic regulator of neurogenesis implicated in 
schizophrenia) has been demonstrated to be fundamental for the regulation of the dendritic 
development of newborn neurons during adult neurogenesis in the mouse hippocampus (J.Y. Kim 
et al, 2012), suggesting possible involvement of NKCC1 in the pathogenic mechanisms underlying 
schizophrenia. 
Of note, in vitro evidence from Amin and coworkers revealed an imbalance in NKCC1 and KCC2 
expression also in DiGeorge Syndrome (a condition conferring high risk of schizophrenia), which 
caused hyperexcitability of the network recovered by bumetanide application to the neuronal 
culture (Amin et al, 2017).  
Bumetanide treatment in schizophrenic patients reduced the severity of the symptoms and 
hallucinations (Lemonnier et al., 2016; Rahmanzadeh, Eftekhari, et al., 2017), without ameliorating 
the total score of the general positive and negative syndrome scale (PANSS) and the brief psychiatric 
rating scale (BPRS) (Rahmanzadeh, Shahbazi, et al, 2017). Interestingly, intranasal administration of 
oxytocin reduced the severity of symptoms in schizophrenic patients in several studies (Brambilla 
et al., 2016; Davis et al., 2014; Davis et al., 2013; Feifel et al., 2012; Feifel et al., 2010; Fischer-Shofty 
et al., 2013; Gibson et al., 2014; Goldman et al., 2011; Lee et al., 2013; Modabbernia et al., 2013; 
Ota et al., 2018; Pedersen et al., 2011; Shin et al., 2015; Woolley et al., 2017; Woolley et al., 2014), 
but see (Cacciotti-Saija et al., 2015; Caravaggio et al., 2017; Dagani et al., 2016; Horta de Macedo et 
al., 2014; Jarskog et al., 2017). In light of the ability of oxytocin to regulate GABA signaling in fetal 
and newborn rodents (Ben-Ari, 2018; Eftekhari, Shahrokhi, et al., 2014; Khazipov et al., 2008; 
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Leonzino et al., 2016; Tyzio et al., 2006; Tyzio et al., 2014), it is tempting to hypothesize that oxytocin 
exerts its therapeutic effect on schizophrenic patients also by regulating CCCs. A deeper 
investigation of the molecular mechanisms underlying the possible relation between the oxytocin 
system and CCCs could open new avenues for the treatment of schizophrenia and other NDs. 
 
3.6 Tuberous Sclerosis Complex 
 
Tuberous sclerosis complex (TSC) is a multiorgan genetic disorder caused by loss of function 
mutations of the TSC1 or TSC2 genes (van Slegtenhorst et al., 1997). This pathology is characterized 
by the presence of cortical tubers (i.e., dysplastic lesions), source of focal epilepsy, autistic behaviors 
and intellectual disability. Given the imbalance of the NKCC1/KCC2 ratio in epilepsy (Schulte et al., 
2018), the investigation of CCCs in tuberous sclerosis has gained interest. TSC patients present an 
increased NKCC1/KCC2 ratio in extracts from cortical tubers (Ruffolo et al., 2016; Talos et al., 2012). 
An altered GABA reversal potential was also described in Xenopus oocytes injected with membranes 
from TSC patient cortical tissues (Ruffolo et al., 2016). Altogether, these studies suggest a possible 
involvement of NKCC1/KCC2 imbalance in the pathogenesis of TSC in patients. Nevertheless, a 
better investigation of both the pathogenic mechanisms and possible therapies needs to be 
performed in rodent models.  
 
3.7 Neurodevelopmental Abnormalities Caused by Traumatic brain injury  
 
Traumatic brain injury (TBI) is caused by an injury to the brain due to external objects or forces. 
When TBI occurs in early childhood, the cortical and subcortical lesions lead to altered 
neurodevelopmental processes and consequent cognitive defects persisting for the lifetime of the 
20 
 
individual (Bonnier et al., 2007; Jonsson et al., 2013; Keenan et al., 2007). The neurodevelopmental 
damages occurring after a TBI are the result of a cascade of events, called secondary brain injury, 
including damage of the blood-brain barrier, inflammation, excitotoxicity, edema, ischemia and 
neuronal damage (e.g., excitotoxicity, aberrant ionic homeostasis, axonal disconnection and death; 
(Ghajar, 2000; Park et al., 2008). One of the mechanisms underlying this cascade of events is possibly 
an imbalance of NKCC1 and KCC2 expression and function. Indeed, three independent studies found 
that NKCC1 was upregulated in the hippocampus and choroid plexus of traumatic brain injury rat 
models and that bumetanide administration decreased the inflammatory response and neuronal 
damage (Lu et al., 2008; Lu et al., 2006; Lu et al., 2007). Then, other studies confirmed the 
fundamental role of NKCC1 in TBI-induced rodent hippocampal aberrant neurogenesis (Lu et al., 
2015), neuronal and astrocytic apoptosis (Hui et al., 2016; M. Zhang et al., 2017), cerebral edema 
(Lu et al., 2017; M. Zhang et al., 2016),  seizures (Liang & Huang, 2017; F. Wang et al., 2017) BBB 
disruption (J. Zhang et al., 2017) and microvascular failure (Simard et al., 2010). Finally, a recent 
work described decreased KCC2 expression in the rat parietal cortex after TBI, which was rescued 
by melatonin administration leading to amelioration of neural apoptosis and brain edema (Wu, 
Shao, et al., 2016). The deep understanding of the involvement of both NKCC1 and KCC2 in the 
secondary brain injury upon TBI suggests timely pharmacological interventions to prevent the 
consequent neurodevelopmental alterations observed in TBI children. 
 
3.8 Glioma  
 
Gliomas are brain tumors, which generates from glial cells and they represent the most common 
solid tumor of childhood. On the base of their unique properties compared to those affect the 
adults, pediatric gliomas can be considered to be neurodevelopmental disorders (Baker et al., 2016). 
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Studies on humans evidences that the intracellular volume regulation promoted by NKCC1 as well 
as aquaporin 4 support glia cell invasion (Haas, B.R. and Sontheimer H, 2010; Garzon-Muvdi T et al, 
2012; Turner K.L. and Sontheimer H, 2014). NKCC1 appears to be upregulated in different kind of 
glioblastoma and anaplastic astrocytoma tissues. Bumetanide pharmacological treatment or NKCC1 
knock down cause a decrease of cell migration (Garzon-Muvdi T et al, 2012; Turner K.L. and 
Sontheimer H, 2014).  
In particular, bumetanide treatment (25–50 mM) allows a dose-dependent reduction of cell 
migration (Garzon-Muvdi T et al, 2012). Cortical GABAergic excitation around human gliomas concur 
to epileptic activities (Pallud J et al, 2014) and NKCC1 activity is increased (Garzon-Muvdi T et al, 
2012). So, high (Cl-)i levels may be reached through the action of NKCC1, determining changes in 
cell volume and a damaged cell migration. Nevertheless, clinical trials have not been evaluated in 
humans. 
 
4. Down syndrome  
 
Down syndrome (DS), also called trisomy 21, is a genetic disorder caused by the presence of all or 
part of a third copy of chromosome 21. The most important clinical hallmarks of individuals with DS   
are congenital birth defects and the intellectual disability, which gives rise to a reduction of the 
intelligence quotient, learning problems and deficits of memory abilities, particularly related to 
hippocampal functions (Desai, 1997; Nadel, 2003; Antonarakis & Epstein, 2006; Parker et al., 2010 
Dierssen, 2012).  
Most of the studies investigated possible mechanisms involved in cognitive impairment, taking 
advantage of diverse murine genetic models of DS (Dierssen, 2012). The Ts65Dn mouse (Reeves et 
al., 1995) is the most characterized and widely used. These mice are characterized by the presence 
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of an extra chromosome derived from mouse chromosome 16, representing the long arm of human 
chromosome 21, fused to the centromere of the murine chromosome 17 (Antonarakis et al, 2004). 
Interestingly, Ts65Dn mice recapitulate many features of DS. In particular, these mice show 
impairment in neuronal development (Belichenko et al, 2004; Chakrabarti et al., 2010; Chakrabarti 
et al., 2007; Contestabile et al., 2010; Contestabile et al., 2007), defects of synaptic plasticity 
(Contestabile et al., 2013; Costa & Grybko, 2005; Kleschevnikov et al., 2004; Siarey et al., 1999; 
Siarey et al., 1997), impaired hippocampus-dependent memory functions (Contestabile et al., 2013; 
Costa et al., 2008; Fernandez et al., 2007; Reeves et al., 1995), hyperactivity (Escorihuela et al., 1995; 
Reeves et al., 1995; Sago et al., 2000) and sleep disorders (Colas et al., 2008).  In 2015, Deidda and 
colleagues proposed a new perspective about GABAAR transmission in DS (Deidda, et al, 2015). In 
their work, the efficacy and polarity of GABAAR signaling were investigated in adult Ts65Dn mice. 
Surprisingly, they found that GABAergic transmission was depolarizing and mostly excitatory rather 
than hyperpolarizing and inhibitory in adult DS mice. In particular, they described an increase in 
spike frequency in Ts65Dn hippocampal and neocortex acute slices in comparison to WT, both in 
baseline conditions and upon application of GABA. Accordingly, blockade of endogenous GABAA 
signaling by the application of the GABAAR antagonist bicuculline resulted in a reduction in the spike 
frequency in neurons from Ts65Dn brain slices. Interestingly, the same study found that the 
defective GABAergic signaling was due to an increased expression of NKCC1 protein, which they 
found in the entire hippocampus, the CA3-CA1 subregion and cortices of adult Ts65Dn mice 
compared to WT littermates. Interestingly, Deidda and coworkers found increased NKCC1 
expression also in hippocampi from DS individuals, providing a parallel between the animal model 
and humans. Conversely, no changes in KCC2 protein expression both in Ts65Dn mice and DS 
individuals were detected. Considering that the increased expression of NKCC1 is the possible cause 
of the aberrant GABAergic transmission in Ts65Dn mice, Deidda and colleagues evaluated NKCC1 
23 
 
inhibition by bumetanide as a potential therapeutic strategy. Bath application of bumetanide was 
able to rescue ECl, with a reduction of spontaneous spiking activity and a decrease in the GABA-
induced spike frequency in acute hippocampal slices of adult Ts65Dn mice. Moreover, bumetanide 
bath application to acute brain slices was able to recover the hippocampal CA1-CA3 LTP to WT levels, 
with no effect on the LTP in WT mice. Finally, Deidda and colleagues tested Ts65Dn mice and their 
WT littermates in three independent behavioral tasks to assess hippocampus-dependent long-term 
explicit memory after either an acute (1 time only), subchronic (1 week) or a chronic (4 weeks) 
systemic (intraperitoneal) treatment with bumetanide. Interestingly, they proved that all three 
treatments with bumetanide were able to fully recover the poor associative memory of Ts65Dn mice 
in the contextual fear conditioning test. Moreover, bumetanide was able to rescue the performance 
of Ts65Dn mice to the level of WT mice in the object-location test, showing a full recovery of spatial-
memory performance. Finally, bumetanide administration was also able to rescue the novel-
discrimination memory of Ts65Dn mice in the novel object recognition test. 
Notably, bumetanide exerted acute activity on NKCC1, and it did not provide long-lasting effects. 
Indeed, a drug withdrawal experimental protocol (i.e., a week of bumetanide washout after a four-
week treatment) completely abolished the rescue observed in both LTP and behavioral tasks, 
indicating the requirement for chronic treatment (Deidda et al, 2015). 
 
 
Beside cognitive impairment, individuals with DS present also with many other health issues (Asim 
et al, 2015). Among them are sleep disorders, which are perceived as one of the problems mostly 
affecting the quality of life of individuals with DS and their family members, possibly also affecting 
cognitive performance (Andreou G et al, 2002). Considering the aberrant GABAergic transmission 
reported in DS (Deidda et al, 2015) and the influence of GABA signaling in sleep, we decided to 
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realize an accurate characterization of sleep and its correlation with mechanisms of Cl- homeostasis 
in Ts65Dn mice. Below is a short introduction to sleep physiology and its regulation by GABAergic 
transmission under physiological condition.  
 
5. Sleep and GABAergic transmission 
 
5.1 Sleep-wake cycle 
  
The sleep-wake cycle is regulated by two main processes: a homeostatic process (S) and a circadian 
process (C). The homeostatic process indicates the propensity of sleep to increase or decrease, that 
depends on the previous wakefulness (Borbely, 2009; Cirelli, 2009). The circadian process is involved 
in dictating the time of sleep and it is self-sustained (C.B Saper et al, 2005; Saper,C.B et al, 2013; 
Waterhouse et al, 2012) (Fig3).  
 
        
Fig3. The sleep-wake cycle regulation by a homeostatic process (S) and a circadian process (C). Orange and blue indicate 





The sleep-wake cycle alternates wakefulness and sleep in a circadian way, where in diurnal species, 
like humans, the wakefulness takes place during daylight hours, while sleep at night. Differently, 
nocturnal animals, such as mice and rats, have a period with greater activity in the dark phase, 
showing during the light phase a much smaller activity (Tobler,1995). 
One of the main regulators of sleep that presents with a circadian rhythm is body temperature.  A 
decrease in temperature is associated to sleep period, whereas an increase of temperature 
coincides with the awakening (P.L Parmeggiani, et al, 1971; P.L Parmeggiani, 1980; P.L Parmeggiani, 
1987). Changes in body temperature have been associated with insomnia (Leon.C. Lack et al, 2008) 
and occur in individuals following sleep deprivation. Sleep deprivation makes subjects more 
vulnerable to heat loss, with less ability to warm themselves to a comfortable temperature (Landic 
CA et al,1998; Masanobu.H et al, 2017). 
The sleep-wake cycle is composed by different arousal states: the wakefulness and an important 
ultradian cycle (less than 24 hours) that includes 90 - 110 minutes cycle of non-rapid eye movement 
sleep (NREM) and rapid-eye movement (REM) in humans. The overall architecture of the sleep-wake 
cycle is well represented by a hypnogram, a graphic representation, showing the hours of recording 





Fig.4. Different phases of the sleep-wake cycle in humans. In horizontal are showed the recording hours (hours of the 
night); in vertical are represented (wake (W), REM sleep (stage R, indicated by orange) and the three sub-stages of sleep 
NREM (stage N1, N2 and N3) (rearranged by Bahammam et al, 2016). 
 
However, rodents have an ultradian cycle with a much shorter duration (10-12 minutes) and a 
polyphasic sleep, rather than monophasic as humans, with an alternation of waking and sleeping 
phases (Tobler,1995; D’Olimpio F and Renzi P, 1998).  
Each phase of sleep-wake cycle is characterized by a particular range of EEG activity and an 
involvement of different brain circuities, which lead to a wide range of behaviors, both during 
wakefulness and sleep. 
From the wakefulness state, we observe usually a transition to NREM sleep phase, which in turn is 
characterized in humans by three different substates (N1, N2 and N3), correlated to increasing 
depth of sleep. The waking state passes to N1, which is a superficial state of sleep, then goes to N2 
and N3, which represent deep stages. In particular, at the beginning of sleep, the transition from 
the waking phase to the N3 occurs very quickly. In this phase, waves of high voltage and low 
frequency predominate in the EEG trace of the substate N3, also called “Slow Wave Sleep” (SWS). 
Then, after a time around 70 minutes in humans sleep enters a REM stage, and then the cycle starts 
again from the N1 phase of NREM sleep. Usually, five NREM and REM sleep cycles alternate, which 
can be interspersed with very brief awakenings. (Carskadon and Dement, 2011).  
However, both NREM and REM phases have shown an importance in synaptic plasticity and 
cognition. Indeed, experiments of REM or non-REM sleep deprivation in rodents have been 
correlated to a decrease in brain plasticity and cognitive performance (Tononi and Cirelli, 2006; 





5.2 The phases of the sleep-wake cycle 
 





The wakefulness state is distinguished by the presence of beta waves (frequency: 15-30 Hz) in the 
EEG recordings during an active waking state, while alpha waves (frequency: 8-12 Hz) are 
predominant in a state of relaxed wakefulness. The cortical activation is involved in the wakefulness, 
and it generates a desynchronized (high amplitude and low frequency) EEG tracing (De Gennaro,L 
and Casagrande,M, 1998) (Fig.5).  
 
 
Fig.5 EEG wakefulness state. Adapted from Lydic et al 2002. 
 
The desynchronization is caused by the neuronal activity originating from the projections departed 
from the reticular formation (RF), a fundamental structure for the state of wakefulness (Lindsley et 
al., 1950; Starzl et al., 1951). Probably, the FC drives its action through the release of the glutamate 
neurotransmitter (Jones, 1995). Notably, the function-mediated by several anesthetics inhibits the 
glutamatergic transmission (Rudolph and Antkowiak, 2004). 
The waking state is also controlled by the locus coeruleus (LC), where noradrenergic transmission 
promotes the excitation of neuronal networks implicated in the waking state, and the inhibition of 
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neuronal networks which supports the sleep (Aston-Jones and Bloom, 1981; McCarley and Hobson, 
1975). Moreover, dopaminergic neurons originating from the substantia nigra, tegmental ventral 
area (VTA) and the grey periaqueductal ventral (vPAG) project in the striatum, cortex and basal 
forebrain (Lu et al., 2006). These projections are characterized by high level of activity during the 
waking state and a very low activity during slow waves sleep (Lena et al, 2005; Maloney et al, 2002).   
The hypothalamus is another important structure for the wakefulness state. In the posterior 
hypothalamic tuberomammillary nucleus (TMN), the neurotransmitter histamine is released to 
promote cortical activation to keep the state of wakefulness, exerting an excitatory effect on the 
ascending reticular activating system (ARAS) and inhibiting the neurons of the ventrolateral preoptic 
area (VLPO) implicated in sleep promotion, through the action of excitatory synapses on inhibitory 
interneurons (Brown et al., 2001b; Saper et al., 2001; Liu et al., 2010). In addition, also 
orexin/hypocretin neurons are projected from lateral hypothalamus to aminergic systems, in 
particular the locus coeruleus (LC) and maintain wakefulness. These neurons inhibit the REM sleep 
and their absence was associated with the insurgence of narcolepsy (Chemelli et al, 1999; Lin et al, 
1999; Mignot et al, 2002; Peyron et al., 2000).   
On the other hand, the mesencephalic structures laterodorsal tegmental nucleus (LDT) and 
tegmental peduncular pontin nucleus (PPT), are implicated in the desynchronization during the 
waking state through the release of acetylcholine. Notably, these structures are also important in 
REM sleep (el Mansari M. et al., 1989; Steriade et al., 1990; Jones, 1995; McCormick, 1992). Finally, 
also serotoninergic neurons located in the raphe dorsal nucleus (DR) and the raphe medial nucleus 
(MR) of the encephalic trunk, project to the neocortex, limbic system and diencephalon. DR and MR 
neurons have the highest firing during the wakefulness, reducing the activity in NREM sleep phase 




5.4 NREM sleep phase 
 
During NREM sleep the features are: a disappearance of muscle tone, a synchronized (low amplitude 
and high frequency) EEG and the absence of rapid ocular movements. NREM sleep phase is mainly 
characterized by delta waves (frequency: 0,5-4 Hz) linked to a deeper sleep, that is defined as “the 
slow wave sleep” (Fig.6). The three stages N1, N2 and N3 of NREM sleep have a greater grade of 
deep sleep and a different brain activity. N1 is linked to the presence of alpha waves, accompanied 
by the first theta waves, N2 shows K complex (bi-triphasic waves, with a high voltage, over 75 μV) 
and sleep spindles, which are waves with a progressive increase and a gradual decrease in the 
amplitude (frequency around 12 - 14 Hz) (Gennaro and Casagrande, 1998; Rechtschaffen and Kales, 
1968; Iber et al., 2007). The last stage, N3, is determined by the onset of delta waves, which reveal 
thalamus-cortical and cortico-thalamic neuronal firings (McCormick and Bal, 1997; McCormick e 
Westbrook, 2001; Steriade et al., 1993; Steriade, 1999). 
 
 
Fig.6 EEG NREM state. Adapted from Lydic et al 2002. 
 
The brain area implicated in the generation of NREM sleep phase is the Preoptic Area (POA) of the 
hypothalamus, where the ventrolateral preoptic nucleus (VLPO) and the Median preoptic area 
(MnPO) are the fundamental regulators of the NREM sleep. Injury of the POA causes the loss of 
NREM sleep, while stimulation increases the percentage of time spent in this phase (McGinty and 
Szymusiak, 2001). VLPO and MnPO neurons make use of inhibitor neurotransmitters as GABA and 
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galanin (gal), which have projections directed to brain area of the ARAS, implicated in the regulation 
of wakefulness (Sherin et al., 1998; Steininger et al., 2001; Uschakov et al., 2007). 
During the sleep VLPO and MnPO neurons show a greater activity during sleep deprivation, 
highlighting their importance in the regulation of sleep homeostasis (Suntsova et al., 2002).  
 
5.5 REM sleep phase 
 
The REM sleep phase, also called paradoxical sleep, show a desynchronized rhythm characterized 
by rapid eyes movements and muscle atony. REM sleep phase is very similar to wakefulness in terms 
of EEG tracing (Fig.7). Nevertheless, the theta waves (frequency: 4-7 Hz), are predominant in the 
EEG recording during REM sleep in the temporal lobal structures of the brain, mostly the projections 
from the hippocampus (McCormick e Westbrook, 2001). 
 
 
Fig.7 EEG REM state. Adapted from Lydic et al 2002. 
 
The most relevant feature that is linked to REM sleep is the experience of dreams. Indeed, 
individuals waked up during this phase mostly remember to have dreamed. However, dreaming is 
also reported in NREM sleep, but less realistic and thought-similar (Dement and Kleitman, 1957; 
Hobson, 2009). Moreover, REM sleep is distinguished by the presence of an irregular respiratory 
and cardiovascular activity (Aserinsky and Kleitman, 2003; Duron, 1972; Coccagna et al., 1971; 
Dufour and Court, 1977; Lacombe et al., 1988; Meunier et al., 1988). Notably, the homeostatic 
mechanisms of body thermoregulation that works normally in the other phase appear to be absent 
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during REM sleep (Dickerson et al., 1993; Parmeggiani et al., 1971). The main structure involved in 
the REM sleep onset is the pontine reticular formation (PRF) (Jones, 1991). Studies have indicated 
an increase of glutamatergic neurons excitability, particularly in the sublaterodorsal nucleus (SLD, 
sub-lateral dorsal) and the pericoeruleus (PC) of PRF during REM sleep. SLD and PC neurons receive 
projections from mesencephalic areas, which are implicated in the generation of the EEG pattern 
typical of REM sleep (Sakai et al., 1979; Sakai, 1986). Moreover, other two neuronal systems are 
responsible of REM sleep regulation: the cholinergic system involved to activate the REM phase 
(Mitani et al., 1988; McCarley, 2007)  and the monoaminergic system, which promotes the inhibition 
of REM sleep (Hobson et al., 1975; Aston-Jones and Bloom, 1981; Hobson et al., 1983; Lydic et al., 
1987a; Lydic et al., 1987b; Trulson and Jacobs, 1979).  Finally, also the GABAergic system regulates 
the REM sleep especially in PRF. In particular, different kind of GABAergic neurons are involved in 
the REM sleep: GABAergic neurons REM-on of the sub-later dorsal nucleus (SLD), which inhibit 
neurons of the monoaminergic system and GABAergic neurons REM-off of the lateral nucleus of the 
Pontine tegmentum (LPT) and of the periaqueductal ventral-lateral gray (vlPAG), which avoid the 
activation of REM-on system of PRF (Boissard et al, 2002; Boissard et al., 2003; Lu et al., 2006). 
Notably, the Ach regulates GABAergic neurons REM-on and REM-off during wakefulness and NREM 
sleep phase (Brown et al., 2012). 
 
5.6 Circadian rhythms 
 
The daily solar cycle determines several and regular changes in terms of light, temperature, and 
food availability in the environment. So, the presence of an internal biologic timer, common to 
almost all organisms including humans, allows the regulation of physiology and behavior in order to 
anticipate daily changes of the day/night cycle.  
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Some processes such as absorption, metabolization and production of fatty proteins, hormones and 
other biological components must take place at a precise time. Optimizing these physiological 
processes means ensuring proper cell development, reproduction and repair.  
The circadian rhythms give rise to circadian oscillations in gene expression regulated by the core 
clock genes, protein modification, and behavior. It is important that these circadian rhythms are 
synchronized and adapted to the external environment, in particular to factors such as light, 
temperature, predation and food availability. These environmental signals, or time-givers are called 
“zeitgebers”. The particularity of circadian rhythms is that they have their own internal regulation, 
but that it can be influenced by external signals in order to synchronize with the environment. The 
circadian clock plays a fundamental role in the physiology of living organisms by controlling the 
sleep/wake cycle, reproduction, thermoregulation and metabolic control. Human physiology is 
based on the daily rhythm of activity and sleep. In particular, the activity requires the internal 
organization of the organs belonged to the digestive system during the day, while the sleep 
suspends most of these processes promoting other activities such as cellular repair, toxin removal 
and memory consolidation. Therefore, circadian rhythms have a great impact on life and their 
impairment could strongly alter our health and well-being. (Pittendrigh C.S, 1993; Foster R.G and 
Kreitzman L, 2004; Dunlap J.C et al, 2011).  
Underlying the control of circadian rhythm is a molecular mechanism based on a positive and 
negative transcriptional feedback loop that involves different genes. These include Clock and Bmal1 
that encode for proteins which give rise to a heterodimer involved in a positive feedback circuit 
which determines the activation of many genes. Among the genes that are activated Per (Per1 and 
Per2) and Cry (Cry1 and Cry2) are involved in the activation of a negative feedback circuit, where 
PER and CRY proteins dimerize by inhibiting the clock. Next, CLOCK-BMAL1 heterodimer promoting 
33 
 
the transcriptional activity, determining a cycle repetition starting from low transcription levels 




Fig8. Core circadian clock. Clock and Bmal1 feedback (+) circuit. CRY and PER feedback (-) circuit. 
 
 
5.7 GABA in sleep and circadian rhythms   
 
GABAergic transmission is a key regulator of sleep (Stenberg D, 2007). GABA is increasingly 
recognized as an important neurotransmitter for the initiation and maintenance of sleep (Morgan 
PT et al, 2012). Hypothalamic GABAergic neurons have projections able to inhibit the firing of cells 
that promote wakefulness. Inhibited neurons include neurons containing norepinephrine, 
serotonin, glutamate, hypocretin, histamine, and serotonin (Siegel Jerome M, 2004).  
Notably, studies have suggested how GABAergic signaling alterations may play a role in the etiology 
of chronic insomnia (Plante et al, 2012). For example, reduced levels of GABA are presented in 
patients with primary insomnia (Morgan PT et al, 2012; Plante et al, 2012). In addition to this, 
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treatment with GABAB receptor antagonists leads to enhanced behavioral states linked to brain 
activation (wakefulness and the dreaming stage during sleep) (Gottesmann C, 2002). 
Moreover, low levels of GABA have been associated with difficulty in falling asleep, whereas high 
levels of GABA are involved in promoting sleep (Bollu and Kaur, 2019). Nevertheless, high GABA 
levels also prevent the achievement of deep sleep stages, which are essential for rest and the 
recovery. Accordingly, the use of benzodiazepines and barbiturates, drugs that act on the GABAA 
receptor opening frequency by increasing the effect of GABA, leads to a greater speed in falling 
asleep, enhance the slow-wave sleep, promote fewer nocturnal awakenings, but generate problems 
in reaching the REM sleep phase (Gottesmann C, 2002).  
Another way in which GABA can influence sleep is through the regulation of circadian rhythms, 
which are involved in the regulation of the sleep-wake cycle (Cirelli C, 2009). Indeed, GABA has a 
key role in the function of this master circadian pacemaker and represents the main 
neurotransmitter of a tiny hypothalamic structure involved in the control of circadian rhythms called 
“suprachiasmatic nucleus” (SCN) (Shlomo Wagner et al, 2001; Nygård M and Palomba M, 2006). In 
mice, GABA exerts a dual effect on neurons in the SCN, excitatory during the day and inhibitory at 
night. This is due to changes in [(Cl−)]i  during the circadian cycle. Interestingly, SCN neurons show a 
huge number of somatic GABAA receptors, which contribute to a modifiable, tonic Cl− conductance. 
In fact, studies showed that two different mechanisms of Cl− transport operated by NKCC1 and KCC2 
are in place in SCN neurons. NKCC1 action is implicated in the accumulation of Cl- inside the cells, 
and KCC2 action is implicated in removing Cl− from cells. The process of replenishment is less 
efficient during the subjective night in the light phase, that is the period when mice are common to 





6. DS and sleep disorders 
 
One of the major causes of sleep disorders in DS is sleep apnea (OSA). This is mostly due to the 
particular craniofacial profile of DS people, the overweight and the alterations of muscle tone of 
upper airways (Andreu G et al, 2002; Donnelly LF et al, 2004). Nevertheless, there is a component 
of the sleep abnormalities of DS people which is independent of OSA. Indeed, individuals who 
underwent to upper airway surgery improving OSA, have continued to report important sleep 
disorders (Dudoignon et al, 2017).  
Sleep disorders of DS people are characterized by an increase of wakefulness with a prolonged sleep 
latency (in particular for NREM phase) and an amount of sleep fragmentation during the night, 
followed by light sleepiness during the day. Other prominent features are the reduction of the REM 
sleep phase (with a decrease of alpha power) and alterations in the waking EEG (slower alpha band 
and/or a theta band power increment) (Grubar JC et al, 1986; Diomedi M et al 1999; Levanon A, et 
al, 1999). However, circadian rhythms result to be unaffected by trisomy (Fernandez et al, 2017), 
suggesting that sleep disorders are independent by a desynchronization of the circadian clock. 
 
7. Animal models of DS and sleep disorders  
 
While various studies on humans have shown the mentioned changes in sleep, the knowledge about 
the sleep of the different animal models of DS are really based on very few and limited experiments. 
So far, research works have displayed only the disruption in the rest activity patterns and 
hyperactive episodes and no change of wake, NREM, and REM sleep phase, with a moderate sleep 
rebound after sleep deprivation in Ts1Cje mice (Colas et al, 2008). Fragmented patterns of sleep-
like behavior have been observed in Tc1 mice, during the light phase with a prolongation of 
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wakefulness at the beginning of the dark phase (Heise et al, 2015). Other studies on Dp(16)1Yey/+ 
mice have reported an increase of wakefulness during light and dark phases and an enhanced 
activity during light phase. In addition to this, the EEG of these mice indicated alterations, with a 
decrease of NREM phase linked to delta power reduction (Levenga J et al, 2018). Similar sleep 
abnormalities were found in Ts65Dn mice, which show an increase of wakefulness during dark 
period with a decrease of NREM sleep phase (low frequency range including delta) and a slight 
increase of REM sleep amounts in the light period. Moreover, T65Dn mice have a delayed but 
increased sleep rebound after sleep deprivation (Colas et al, 2008). No alterations were found for 
circadian rhythms (Stewart et al, 2007), confirming results linked to DS individuals. 
Although sleep patterns have been addressed in numerous mouse models of DS, the results have 
included one only study per mouse model. Moreover, all studies lacked the evaluation of activity, 
body temperature and metabolism, which are other factors that could be decisive in influencing the 
course of sleep (C Leon Lack et al 2008; Owens J A, 2009; Sharma and Kavuru, 2010).  
 
8. Current treatment and clinical trials for DS   
 
There is no pharmacological treatment for cognitive deficits in DS, only few clinical trials under 
development. Bartesaghi’s group has promoted fluoxetine (Prozac – drug approved for depression), 
an inhibitor of serotonin reuptake, where the first clinical trial for safety in DS soon recruiting. 
However, mechanism of actions of fluoxetine are not known for DS. Finally, fluoxetine is a 
psychotropic drug, which is causing doubts in parents and difficulty in recruiting for the trial. 
Another study supported by de la Torre’s group support the use of epigallocatechin-3-gallate (EGCG, 
phytochemical derived from green tea), an inhibitor of DYRK1A kinase. Also, for this treatment there 
are drawbacks such as that the mechanism of action is not known for DS; green tea active substance 
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is unknown; and there is a poor efficacy in clinical trials in young adults with DS (NCT01394796 and 
NCT01699711). An additional trial (NCT03624556) in pediatric patients with DS or Fragile X 
syndrome is currently recruiting.  
Finally, Costa’s group has proposed memantine hydrochloride (Namenda - drug approved for 
Alzheimer-type dementia), an antagonist of NMDA-Receptor. Also, in this case the mechanism of 
action is not known for DS, and poor efficacy was reported in a clinical trial in adults (NCT01112683) 
with DS. Nevertheless, an additional trial (NCT02304302) in young adults with DS currently 
recruiting.  
 
9. Prader-Willi syndrome 
 
PWS is a rare genomic imprinting or epigenetic disorder, with an incidence estimated at the birth of 
approximately 1/15,000–1/20,000 individuals (Soni S et al, 2008).  
PWS is caused by alterations linked to allele paternal chromosome 15 (15q11-q13) deletion. The 
loss of paternal genetic inheritance characteristic of PWS, can originate from the partial or total 
deletion of the q11-13 region (65-75 %) or a maternal uniparental disomy 15 (UPD) (20-30%) with 
the presence of two copy of maternal chromosome 15 or the absence of chromosomal paternal 
copy. Notably, other cases of PWS arise for imprinting defects (1-3%) (Cassidy SB et al, 2012) (Fig.9).  
A recent scientific research has highlighted the existence of two different sites of the breakpoint 
involving the deletion: Type 1 (T1D) and Type (T2D). T1 comprises the breakpoint site 1 (BP1), which 
is found in the centromere zone of chromosome 15, T2 includes the breakpoint 2 (BP2), placed ~500 
kb distal to BP1. Therefore, T1 involves an additional zone of genetic material in comparison to T2 









Fig10. Breakpoint 1 and 2 involving in the generation of T1 or T2 deletion of chromosome 15 (15q11-q13) 





PWS is mainly characterized by developmental abnormalities, behavioral deficits, sleep disorders 
and metabolic dysfunctions. Developmental abnormalities comprise neonatal hypotonia, growth 
retardation, short stature, frequent hypogonadism and defects in brain region showing lower 
brainstem volume, and a trend towards a reduction of cortical surface area and white matter 
volume (Lan An Thuy, 2017; Whittington J and Holland A, 2017; Miscogiuri et al, 2019).  
The most important PWS features are associated with an impulsive tendency to feeding getting into 
obesity, an intellectual disability from mild to moderate, a high presence of separation anxiety in 
childhood (Steinhausen et al, 2004), aggressive behavior, impulsivity and hyperactivity related to 
attention deficit hyperactivity disorder (ADHD), psychosis aspects, obsessive-compulsive-behaviors 
during the adulthood and sleep disorders (Gillet and Perez, 2016; Guinovart et al, 2019). Peculiarly, 
children with PWS show poor feeding and lack of appetite in infancy, developing an uncontrolled 
appetite with lack of satiety that get to weight gain, mostly after the age of 2–3 years (Crinò et al, 
2018). Moreover, seizures are also reported in some patients (Verrotti et al, 2014).  Thus, many of 
these hallmarks common to other NDDs maybe also related to altered intracellular Cl- concentration 
and depolarizing GABAergic signaling. In addition to this, PWS is also related to deficits of sociability, 
emotional states and joint attention (Dickens et al, 2019). In particular, a relationship between PWS 
and specific certified clinical features of autism spectrum disorder (ASD) is present in approximately 
40% of people with PWS due to UPD, 15–18% of PWS cases due to deletions (Dyckens et al, 2011).   
The imprinting defect leads to the loss of genes expression on allele paternal chromosome locus 
15q11-q13, while the same region linked to maternal chromosome is involved to the onset of 
Angelman syndrome (AS), highlighting a key role in the expression of these genes (Nicholls, 2000). 
Among the lack of genes caused by the deletion on paternal chromosome 15 in PWS, SNORD116 
(also called H/MBII-85), plays a critical role on the clinical phenotypic manifestation of PWS. Indeed, 
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PWS individuals, presenting deletion of SNORD116 gene only, present with the typical phenotypic 
features associated to PWS (Bieth E et al, 2015).  
Snord116 is a cluster of small nucleolar/noncoding RNAs (snoRNAs), mainly expressed in the brain, 
which are involved in the control of the expression of other small nucleolar RNAs (Sahoo et al, 2008). 
Lack of Snord116 in different mouse models with deletion of diverse lengths (all including Snord116) 
lead to growth deficiency, hyperphagia, cognitive alterations and sleep disorders (Ding et al, 2008; 
Lassi et al, 2016; Lassi, Maggi, et al 2016; Adhikari et al, 2018). Nevertheless, how Snord116 affects 
these functions remains still unclear. 
Among the experimental models, the mouse mutant PWScrm+/p−, carry a very restricted deletion just 
involving Snord116 and IPW (imprinted gene in the Prader Willi syndrome region) exons A1/A2, B, 
and C, which is a maternally imprinted gene related to the PWS and AS imprinted domain on human 
chromosome 15 and mouse chromosome 7, probably implicated in mechanisms of regulation of 
imprinting (Wevrick R et al, 1994; Skryabin BV et al, 2007).  Thus, PWScrm+/p− represents one of the 
best models to examine the specific phenotype associated with the absence of Snord116. 
PWScrm+/p− mutant mice are characterized by postnatal growth retardation, a major reduction in the 
size of the hippocampus and sleep disorders (Skryabin BV et al, 2007; Lassi et al, 2016). However, 
only few studies have been executed on PWScrm+/p− and these studies did not include cognition and 
other behaviors correlated to ASD and anxiety disorders. 
 
10. Cognition and PWS 
 
Cognitive deficits in PWS individuals are characterized by impairment in memory, a low intelligent 
quotient (IQ), impairment to elaborate an abstract idea, and difficulties of comprehension (Warren 
and Hunt, 1981; Bertella et al, 2005; Whittington and Holland, 2017). Interestingly, performances 
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on basic literacy and numeracy are very variable in PWS, but they shared a decline of the attainment 
with age (Whittington et al, 2004). Generally, language development is delayed and compromised, 
presenting problems in the articulation, which need speech therapy (Whittington et al, 2002). In 
particular, different studies, (Chen et al, 2010; Dimitropoulos et al, 2013 a,b), have shown that 
expressive language is more damaged than receptive language. Moreover, people with PWS also 
reported impairments of auditory modality in an event-related brain activity study (Stauder et al, 
2002), and low scores relative to investigations of executive functions, with a severe impairment of 
working memory and a slight impairment in tasks evaluating the inhibition (Jauregi et al, 2007; 
Chevalere et al, 2015).  However, smaller brain volumes and less cortical complexity, probably are 
responsible for low IQ, while specific disorders of executive functions and language may be related 
to specific brain areas (Manning and Holland, 2015; Whittington and Holland, 2017).  Anyway, 
clinical diagnostic criteria for PWS enclose excellent abilities with jigsaw puzzles and a lot of time 
doing them (Verdine et al, 2008).   
Finally, social cognition is commonly impaired in PW, with the presence of absent or very poor peer 
group relationship, similarly to features associated to ASD (Dykens EM et al, 2019). For example, 
some studies indicated that the observance of social norms are not well considered in individuals 
with PWS (Dimitropoulos et al, 2013 a,b), disturbing conversation and invading others’ personal 
space (Lo et al, 2013). 
 
11. PWS mouse models and cognition 
 
Studies on mouse models of PWS started in 1992 aimed at looking at physical and behavioral 
characteristics, particularly feeding behavior, size, weight, and hypotonia. Cognition was 
investigated only later (Whittington and Holland, 2017). 
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In particular, an imprinting centre deletion mouse model of PWS (PWS-IC) has reported reduced 
attentional capabilities using a five-choice serial reaction time task (5-CSRTT) decreasing accuracy 
and presenting a greater number of omissions and longer correct reaction times in comparison to 
wild type mice. Interestingly motor function and motivation were not significantly impaired 
compared to controls in these same mice. Remarkably, these results are comparable to features of 
people with PWS (Relkovic et al, 2010). Of note, PWS-IC model has shown better performances, 
spending less time to reach criteria and few errors, during acquisition and reversal learning in a 
behavioral test based on the influence of palatable food reward on learning. Probably, this cognitive 
effort can be explained considering the importance of food acquisition for people with PWS 
(Relkovic et al, 2012). 
Impairments in social recognition, social interaction and a reduced learning ability were found in 
adult male mice lacking the Magel2 gene (M2−), while no cognitive deficits were showed in female 
M2−mice. However, working memory tested in the Y-maze remained unchanged independently of 
gender (Meziane et al, 2015). Social deficits were displayed for a Maged1 knock-out mouse model 
(Dombret et al, 2012). Conversely, investigations on spatial learning and memory in Necdin deficient 
mice using the Morris water maze indicated that the mutants reported better memories for the 
platform location (Muscatelli et al, 2000). 
Researches based on the lack of SnoRNA with a deletion of the 40+ copies of Snord116, have showed 
a normal short-term working memory measuring rates of spontaneous alternation in the Y maze, 
motor learning deficiency between WT mice and mutant mice (Ding et al, 2008). In addition, 
experiments on Snord116+/- mutant mice, carrying a ~150 kb deletion of Snord116, have reported 
deficits in the learning and memory abilities using the novel object recognition, location memory 
and tone cue fear conditioning assays compared to littermate control Snord116+/+ mice (Adhikari et 
al, 2018). Anyway, in the model PWScrm+/p− with the restricted deletion involving Snord116, has a 
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better performance and decision making in the working-for-food task have been confirmed (Lassi 
et al, 2016). These results highlight the strong cognitive effort to eat in PWS. 
 
12. Psychopathologies and PWS  
 
The various psychopathological traits associated with PWS are very varied and most patients report 
generalized anxiety. Interestingly, anxiety-related and depressive disorders have been associated 
with genetic modifications involving the region of chromosome 15 responsible for the PWS. Several 
cases of patients showing anxiety symptoms also reported outbursts of anger. However, the most 
overwhelming (or preponderant cases of mental illness) have been seen in UDP cases. This suggests 
the importance of the genetic component in PWS disorders (Guinovart et al, 2019).  
PWS is one of several disorders associated with autism. This is probably because the region 15q11p-
13 represents a place of significant impact on ASD susceptibility genes. In particular, PWS individuals 
exhibit repetitive behaviors, which may be different in type among the various subjects, and they 
are more expressed in males. Among the obsessive-compulsive disorders, self-injurious behavior is 
a very present feature, especially skin picking (Dykens et al, 2011).  
Furthermore, PWS individuals also report communicative impairments and social interaction issues 
(Dimitropoulos A, 2013b). For example, during experiments of face processing, PWS people present 
eye-tracking alterations similar to ASD people (Dalton KM et al 2005; Klin A et al, 2002). Moreover, 
PWS individuals perform poorly in the social attribution task, again similarly to ASD individuals 
(Koenig K et al, 2004). 
A hypothesis to explain the psychopathological traits that are often associated with PWS may be the 
implication of the GABAergic system. Indeed, the deletion region of PWS chromosome 15 contains 
the genes implicated in the coding of the alpha5 and beta3 subunit of the GABAA receptor. These 
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GABAA receptors present a reduction in the number and abnormalities in the subunit composition 
in the neocortex and in the insula of PWS individuals (Lucignani G et al, 2004). 
In addition, low levels of GABA have been reported using single-voxel proton magnetic resonance 
spectroscopy (1H-MRS) in PWS people (Rice L.J et al 2016).  
 
13. Current treatment and clinical trials for PWS 
 
Obesity and hyperphagia are mostly involved to induce morbidity and mortality in PWS that needed 
an accurate diagnosis, appropriate medical management and treatment (Butler et al, 2016). 
Management is actually operated by multidisciplinary teams including clinical geneticists, 
endocrinologists, dietitians, primary care physicians and mental health experts who aim to regulate 
weight gain, monitoring the diet and give a specific treatment to comorbid conditions associated 
with PWS (Butler MG, 2006; Soni.S et al, 2007; Goldstone AP et al, 2008; McCandless SE et al, 2011). 
Hyperphagia and obesity complications can be managed by strict control of the diet and practicing 
regular exercise plans. Therapies with the goal to replace growth and sex hormones represent other 
significant strategies involved in the management (McCandless SE et al, 2011; Griggs.G et al, 2015). 
 
However, problems related to cognition are also very important, preventing a normal course of life 
for these individuals inside society. Therefore, the necessity of a clinical treatment in order to allow 
an improvement of intellectual disabilities of PWS appears to be essential. 
So far, only the growth hormone treatment has produced beneficial effects on cognition in children 
and adults with PWS (Grugni and Marzullo 2016).  This was described in different case studies (Vogt 
KS and Emerick JE, 2015; Dykens et al, 2017, Lo ST et al, 2015) But this treatment commonly 
prescribed in PWS during infancy, childhood and adolescence may worsen scoliosis (Murakami N et 
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al, 2012; Deal CL et al, 2013) and the safety of treatment is not well clarified. Moreover, therapies 
or clinical trials to improve symptoms of PWS related to ASD have not been carried out yet. 
 
 
Thus, new therapeutic approaches for the treatment of cognition and ASD in PWS is urgently 
needed. In this context, the study of Cl- homeostasis represents a still unexplored field of the 
research (Lucignani G et al, 2004; Rice L.J et al 2016) in animal models and individuals with PWS. 
From a growing literature that describes the involvement of an aberrant chloride homeostasis in a 
very high number of pathologies of neurodevelopment (Ben-ari, 2017) that share with PWS various 
symptoms, our desire is born to investigate the mechanisms underlying the action of the GABA 












Aim of Project  
 
1. The role of Cl- homeostasis in sleep disorder of DS 
 
In the recent past, Deidda et al. proposed that GABAergic transmission, which is normally 
hyperpolarizing and inhibitory in adult WT animals, is depolarizing and possibly excitatory in adult 
DS mice. Accordingly, they demonstrated that DS mice overexpress NKCC1, leading to higher [Cl-]i 
and depolarizing/excitatory Cl- efflux upon GABAA-receptor activation. Surprisingly, NKCC1 
inhibition by the FDA-approved diuretic bumetanide has shown to be able to rescue inhibitory 
GABAergic transmission, synaptic plasticity and cognitive functions in adult DS mice (Deidda et al, 
2015).  
The alteration of GABAergic transmission due to upregulation of NKCC1 in DS might be a reason of 
sleep disturbances. This is useful to shed light on whether defective Cl- homeostasis is involved in 
sleep alteration in adult DS mice, and possibly to indicate bumetanide as a therapeutic approach to 
ameliorate sleep disorders in DS patients. Thus, we propose an in vivo study of sleep and its relation 
to altered Cl- homeostasis in adult TS65Dn mice, the most used animal model of DS (Reeves et al., 
1995; Escorihuela et al., 1995; Reeves et al., 1995; Siarey et al., 1997; Siarey et al., 1999;  Sago et al., 
2000; Belichenko et al, 2004; Kleschevnikov et al., 2004; Costa & Grybko, 2005;  Chakrabarti et al., 
2007; Contestabile et al., 2007; Fernandez et al., 2007;  Colas et al., 2008; Costa et al., 2008; 
Contestabile et al., 2010; Chakrabarti et al., 2010; Contestabile et al, 2013). 
We used a unique setup that allows the simultaneous and synchronized monitoring of EEG, 
temperature and activity along the 24 hrs.  So, we investigated about a possible implication of an 
aberrant GABAergic transmission on sleep and whether rescuing an impaired Cl- homeostasis by 
bumetanide could normalize the sleep-wake cycle in adult Ts65Dn mice. 
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2. The role of Cl- homeostasis in behaviors and circadian rhythms of PWS 
 
PWS is a neurodevelopmental disorder characterized by anxiety, cognitive alterations, sleep 
disorders and ASD behaviors (Steinhausen et al, 2004; Dykens EM et al, 2019; Guinovart et al, 2019; 
Miscogiuri et al, 2019). As in a growing number of neurodevelopmental disorders these same health 
issues have been associated to impaired intracellular Cl- homeostasis (Ben-Ari, 2017), we decided to 
evaluate possible changes in the expression of the two chloride co-trasporters NKCC1 and KCC2 in 
a in a mouse model of PWS (PWScrm+/p− mouse model of PWS) in the diverse brain regions. We 
conducted our experiments in the PWScrm+/p− mice.  This mouse model has the shortest deletion of 
the chromosome 7, just involving Snord116 and IPW exons A1/A2, B, and C (Wevrick R et al, 1994; 
Skryabin BV et al, 2007). We chose this model because it was the best to specifically recapitulate 
PWS symptoms, considering that SNORD116 deletion is mostly implicated in the phenotypic 
manifestations of PWS (Bieth E et al, 2015). Then, we investigated the impact of altered Cl- 
homeostasis on cognition, anxiety and ASD behaviors in PWScrm+/p− compared to WT. Finally, we 
also investigated possible abnormalities in the circadian rhythm of PWS mice and its Cl- dependence.  
 
Results: The role of Cl- homeostasis in sleep disorder of DS 
 
All experiments were performed in collaboration with Dr. Tucci’s lab (Neurobehavioural Genetics 
group). EEG recordings led to  a detailed overview during the day-night cycle on wakefulness analysis 
(Fig.11), NREM (Fig.12,Fig.15, Fig.16), REM (Fig.13,Fig.17,Fig.18), and total sleep (Fig.14) of wild type 
(WT) and Ts65Dn (Ts) mice (3-4 month old) treated with vehicle (WT_VE and Ts_VE saline) and 
bumetanide 2mg/ml in drinking water (WT_BU and Ts_BU), following the experimental procedure 






Scheme1. Representation of experimental procedure 
 
 
In total, 24 animals were treated (6 WT_VE, 6 Ts_VE, 6 WT_BU and 6 Ts_BU) before (Fig.11-15, 17) 
during and after sleep deprivation (SD) of 6 h (Fig.11-14, 16,18). Through the same wireless devices, 
we also performed the analysis of activity and temperature (Fig.19-22) during the 24 hours.  
 
1. Bumetanide decreases abnormal wakefulness at the early stage of light phase and 
improves sleep quality in Ts65Dn mice 
 
During the 24 hours of EEG recordings, the amount of wakefulness was greater in Ts_VE mice than 
WT_VE in the light period at baseline (Fig.11A). Interestingly bumetanide treatment decreases this 
abnormal wakefulness in the light period. Indeed, no differences emerged by bumetanide treatment 
in Ts_BU compared to WT_VE at baseline, but a significative increase of wakefulness amounts were 
reported in the recovery after SD (Fig.11B). However, the comparison between WT_VE and WT_BU 
(Fig.11C), did not shown any significative effect, as well as, Ts_VE and Ts_BU (Fig.11D).  
Moreover, we reported an alteration of architecture of sleep with a reduction of amount of NREM 
sleep across light phase in Ts_VE compared to WT_VE at baseline and after SD (Fig.12A). Of note, 
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we displayed a decrease in NREM sleep amounts of Ts_BU respect to WT_VE though light phase at 
baseline and in light and dark phase during the recovery (Fig.12B).  No statistically significant 
difference was found between WT_VE and WT_BU, as well as, Ts_VE and Ts_BU (Fig.12C, D).  
As regards the REM sleep phase, we did not find any alteration difference between WT_VE and 
Ts_VE (Fig.13A), WT_VE and WT_BU (Fig.13C), and Ts_VE and Ts_BU (Fig.13D). Peculiarly, we 
showed a reduction of amount of REM sleep in Ts_BU compared to WT_VE across dark period after 
SD, (Fig.13B). 
In addition to this, analysis on the total sleep have confirmed a statistically significant decrease of 
sleep in Ts_VE compared to WT_VE during light at baseline (Fig.14A) and a lowering sleep amounts 
in dark phase after SD in Ts_BU (Fig.14D).  
Further analyses were performed on the spectral characteristics of the EEG. EEG power density was 
compared for delta (0, 5–4 Hz) (Ito J et al, 2014) and theta (5–10 Hz) (Tort A. BL. et al, 2018) in NREM 
and REM sleep phases, as an indication of the sleep quality across 24h at baseline and 18h after SD. 
We found a statistically significant reduction of delta power during NREM and an increase of theta 
power before and after SD in Ts_VE compared to WT_VE (Fig.15A and Fig.16A). Interestingly, we 
reported an improvement of power density of delta and theta power in Ts_BU compared to Ts_VE 
(Fig.15D and Fig.16D), towards the level of WT_VE at baseline and after SD (Fig.15B and Fig.16B). 
No differences have shown in the comparison between WT_VE and WT_BU (Fig.15C and Fig.16C). 
In addition, we showed a statistically significant increase of theta power density in Ts_VE compared 
to WT_VE before and after SD, and a decrease of delta power at baseline (Fig.17A and Fig.18A). 
Peculiarly, Ts_BU mice present a lower power density of theta compared to Ts_VE before and after 
SD (Fig.17D and Fig.18D), improving theta power towards the level of WT_VE (Fig.17B and Fig.18B). 
Moreover, Ts_BU also show an improvement of delta power at baseline towards the level of WT_VE 
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Fig.11. Amount of the epochs number of wake, per two hours, across the 24 h in A) 6 WT_VE versus 6 Ts_VE, B) 6 WT_VE 
versus 6 Ts_BU, C) 6 WT_VE versus 6 WT_BU  D) 6 Ts_VE versus 6 Ts_BU at baseline, sleep deprivation (SD) and in the 
recovery after SD. An epoch is intended 4 seconds of EEG registration period. All graphs are presented as mean ± SEM 
across 24 h. Light and dark phases are indicated respectively by the yellow and white on each graph. Statistical 







Fig.12. Amount of the epochs number of NREM, per two hours, across the 24 h in A) 6 WT_VE versus 6 Ts_VE, B) 6 
WT_VE versus 6 Ts_BU, C) 6 WT_VE versus 6 WT_BU D) 6 Ts_VE versus 6 Ts_BU at baseline, sleep deprivation (SD) and 
in the recovery after SD . An epoch is intended 4 seconds of EEG registration period. All graphs are presented as mean 
± SEM across 24 h. Light and dark phases are indicated respectively by the yellow and white on each graph. Statistical 





Fig.13. Amount of the epochs number of NREM, per two hours, across the 24 h in A) 6 WT_VE versus 6 Ts_VE, B) 6 
WT_VE versus 6 Ts_BU, C) 6 WT_VE versus 6 WT_BU D) 6 Ts_VE versus 6 Ts_BU at baseline, sleep deprivation (SD) and 
in the recovery after SD . An epoch is intended 4 seconds of EEG registration period. All graphs are presented as mean 
± SEM across 24 h. Light and dark phases are indicated respectively by the yellow and white on each graph. Statistical 






Fig.14. Amount of the epochs number of NREM, per two hours, across the 24 h in A) 6 WT_VE versus 6 Ts_VE, B) 6 
WT_VE versus 6 Ts_BU, C) 6 WT_VE versus 6 WT_BU D) 6 Ts_VE versus 6 Ts_BU at baseline, sleep deprivation (SD) and 
in the recovery after SD.  An epoch is intended 4 seconds of EEG registration period. All graphs are presented as mean 
± SEM across 24 h.Light and dark phases are indicated respectively by the yellow and white on each graph. Statistical 











Fig.15. EEG power densities of the whole spectrum of frequencies (μV2 ) during NREM sleep at baseline in A) 6 WT_VE 
versus 6 Ts_VE B) 6 WT_VE versus 6 Ts_BU, C) 6 WT_VE versus 6 WT_BU D) 6 Ts_VE versus 6 Ts_BU.  =*P<0,05,   = 














Fig.16. EEG power densities of the whole spectrum of frequencies (μV2) during NREM sleep after sleep deprivation in 












Fig.17. EEG power densities of the whole spectrum of frequencies (μV2) during REM sleep at baseline in A) 6 WT_VE 














Fig.18. EEG power densities of the whole spectrum of frequencies (μV2) during REM sleep after sleep deprivation. A) 6 
WT_VE versus 6 Ts_VE B) 6 WT_VE versus 6 Ts_BU, C) 6 WT_VE versus 6 WT_BU D) 6 Ts_VE versus 6 Ts_BU.  = P<0,05, 










2. Body temperature is reduced in Ts65Dn mice during dark phases, and bumetanide does 
not have an effect on temperature.  
  
To assess physiological parameters across long-term recording, we recorded the circadian profile of 
body temperature in mice using intraperitoneal implants. Although, Ts_VE mice have not showed 
notable alterations of their body temperature throughout 24 h in both phase light and dark before 
and after sleep deprivation, we found a statistically significant genotyping effect on Ts65Dn mice in 
terms of a lower body temperature in dark phase at baseline (Fig.19A,B and Fig.20A,B).  
Peculiarly, bumetanide treatment has not shown any effect both in WT_BU and Ts_BU mice (Fig.19 
A,B; Fig.20 A,B).  
 
3. Ts65Dn mice display hyperactivity during 24 h hours, partially rescued by bumetanide 
treatment  
Physiological activity of mice was assessed throughout 24 h. It resulted significantly increased in 
Ts_VE mice compared to WT_VE at baseline in light phase (Fig.21A) and presented an elevated trend 
during dark phase (Fig.21B). Interestingly, both conditions are partially rescued by bumetanide 
treatment in Ts_BU (Fig.21A). After SD, we confirmed the increasement trend of activity in Ts_VE, 
during light and dark phase, reduced by bumetanide (Fig.22,A,B). Conversely, no differences 











Fig.19. Body temperature across 24h at baseline in 6 WT_VE, 6 WT_BU, 6 Ts_VE, 6 Ts_BU during light (A) and dark (B) 
period. All graphs are presented as mean ± SEM across 12 h. Statistical significance is represented as follows: P > 0.05, 







Fig.20. Body temperature across 24h after sleep deprivation in 6 WT_VE, 6 WT_BU, 6 Ts_VE, 6 Ts_BU, during light (A) 
and dark (B) period. All graphs are presented as mean ± SEM across 12 h. Statistical significance is represented as follows: 








Fig.21. Activity across 24 h at baseline in 6 WT_VE, 6 WT_BU, 6 Ts_VE, 6 Ts_BU, during light (A) and dark (B) period.  All 
graphs are presented as mean ± SEM across 12 h. Statistical significance is represented as follows: P > 0.05, two-way 






Fig.22. Activity across 24 h after sleep deprivation in 6 WT_VE, 6 WT_BU, 6 Ts_VE, 6 Ts_BU, during light (A) and dark (B) 
period. All graphs are presented as mean ± SEM across 12 h. Statistical significance is represented as follows: P > 0.05, 




4. Ts65Dn mice show an increase in food intake, not reduced by bumetanide treatment  
To evaluate different parameters linked to sleep, we also considered monitoring the food intake of 
mice throughout 24 h, considering the relationship between eating activity and sleep patterns 
reported in literature (Imaki M et al, 2002; Weiss et al, 2010). Notably, we found an increase of food 





Fig.23. Food intake across 24 h in 6 WT_VE, 6 WT_BU, 6 Ts_VE, 6 Ts_BU. All graphs are presented as mean ± SEM across 








Results: The role of Cl- homeostasis in behaviors and circadian rhythms of PWS 
 
1. NKCC1 protein expression is specifically upregulated in the hippocampus of 
PWScrm+/p−mice compared to controls 
 
To investigate whether an alteration of the Cl- homeostasis could be linked to PWS, we first assessed 
the expression level of NKCC1 and KCC2 in the hippocampus from adult (3months) PWScrm+/p−mice 
and their WT littermates by western blot technique. We found that NKCC1 expression was 
significantly increased in PWScrm+/p−mice in comparison to controls (Fig.24a). Conversely, we found 
comparable levels of KCC2 expression in the two experimental groups.  (Fig.24b).  
 
 
Fig.24. NKCC1 protein expression is increased in the hippocampi of PWScrm+/p−mice (a) Top, representative immunoblots 
for NKCC1 in protein extracts from samples of mouse whole hippocampus in PWScrm+/p+ (WT) =9 and PWScrm+/p− (PWS) 
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=9. (b) Top, representative immunoblots for KCC2 in protein extracts from samples of mouse whole hippocampus in 
PWScrm+/p+ (WT) =9 and PWScrm+/p− (PWS)=9. Bottom, quantification of NKCC1 and KCC2 in samples from PWS in 
comparison to WT mice, respectively (*P<0,05 and P>0,05) in a, b respectively, by Student’s t-test. Actin was used as an 
internal standard.  
 
Next, we also evaluated NKCC1 and KCC2 protein levels in the prefrontal cortex (Fig.25), 
hypothalamus (Fig.26) and SCN (Fig.27). In none of these brain regions, we found any significative 
difference both for NKCC1 and KCC2 leves between PWScrm+/p−mice and controls.  
 
 
Fig.25. (a) Top, representative immunoblots for NKCC1 in protein extracts from samples of mouse prefrontal cortex in 
PWScrm+/p+ (WT) =7 and PWScrm+/p−(PWS) =8. (b) Top, representative immunoblots for KCC2 in protein extracts from 
samples of mouse whole hippocampus in PWScrm+/p+ (WT)=7 and PWScrm+/p− =7. Bottom, quantification of NKCC1 and 





Fig.26. (a) Top, representative immunoblots for NKCC1 in protein extracts from samples of mouse whole hypothalamus 
in PWScrm+/p+ (WT) =9 PWScrm+/p− (PWS)=8. (b) Top, representative immunoblots for KCC2 in protein extracts from 
samples of mouse whole hippocampus in PWScrm+/p+ (WT) =9 and PWScrm+/p− (PWS)mice =8.  Bottom, quantification of 
NKCC1 and KCC2 in samples from PWS in comparison to WT mice, P>0,05 in a, b, by Student’s t-test. Actin was used as 




Fig.27. (a) Top, representative immunoblots for NKCC1 in protein extracts from samples of mouse whole SCN in 
PWScrm+/p+ (WT) = 6 and PWScrm+/p−(PWS). (b) Top, representative immunoblots for KCC2 in protein extracts from 
samples of mouse whole hippocampus in PWScrm+/p+ (WT)=7 and PWScrm+/p− (PWS) =6. Bottom, quantification of NKCC1 
and KCC2 in samples from PWS mice with PWS in comparison to WT mice, (P>0,05) in a, b, by Student’s t-test. Actin was 
used as an internal standard.  
 
2. A chronic treatment with bumetanide rescues cognitive deficits in PWScrm+/p− mice. 
 
Upregulation of NKCC1 has been linked to cognitive impairment in Down syndrome mice (Deidda et 
al, 2015). We investigated the possible contribution of increased expression of NKCC1 in cognitive 
behavior of PWScrm+/p− mice by treating the animals with a NKCC1 inhibitor (bumetanide) and then 
assessing their cognitive performance.  In particular, we evaluated the long-term hippocampus-
dependent explicit memory after subchronic, systemic treatment with bumetanide (0.2 mg Kg−1, IP, 
daily; Fig. 28), as described for DS in Deidda et al 2015.   
 
 
Fig.28. Schematic cartoon of the experimental protocol for the treatment of WT and PWScrm+/p−mice with bumetanide 
and its efficacy assessment. 
 
Thus, we assessed the long-term memory in three independent tasks (i.e., novel object recognition 
(NOR), object location recognition (OL), Contextual and Cue fear conditioning). 
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First, we performed the NOR test. This task measures the preference of mice for a novel object 
versus previously encountered familiar objects. 
Interestingly, we found that a poor novelty-discrimination capability during the performance with 
the presence of the new object in PWScrm+/p− in comparison to WT. This deficit was completely 




Fig.29. Schematic representation of NOR. Quantification of the discrimination index in vehicle-treated PWScrm+/p+ 
(WT)=11 and PWScrm+/p− (PWS) =9 or bumetanide-treated PWScrm+/p+ WT=9 and PWScrm+/p− (PWS) =9 in the NOR test 
(*P < 0.05, two-way ANOVA followed by Tukey’s post hoc test). 
 
 
Next, we also evaluated spatial memory in the OL. The test measures the ability of mice to recognize 
the new location of a familiar object with respect to spatial, external cues (Fig.30).  
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Here, we found an impairment of spatial memory in vehicle-treated PWScrm+/p− mice. Bumetanide 




 Fig.30. Schematic representation of the OL. Quantification of the discrimination index in vehicle-treated PWScrm+/p+ 
(WT) =10 and PWScrm+/p− (PWS) =9 or bumetanide-treated PWScrm+/p+ (WT)= 8 and PWScrm+/p− (PWS) =11 in the OL test. 
(*P < 0.01, two-way ANOVA followed by Tukey’s post hoc test). 
 
Finally, we assessed associative memory in the contextual and post cued fear conditioning tests. 
These tasks measure the freezing response that takes place after pairing of a foot shock 
(conditioning) with a particular context represented by a grid releasing an electric shock (Fig.31) or 
after a cue, represented by an acustic signal related to the releasing of the electric shock during the 
day of training. We did not find any difference among groups for any of the two tests However, 
bumetanide significantly increased associative memory in PWScrm+/p− vs vehicle treatment in the 






Fig.31. Schematic representation of the Contextual Fear Conditioning. Quantification of the freezing response in vehicle-
treated PWScrm+/p+ (WT)=10 and PWScrm+/p− (PWS) =10 or bumetanide-treated PWScrm+/p+ (WT)=7 and PWScrm+/p−(PWS) 
=11 in the Contexual fear conditioning test. (P> 0.05, two-way ANOVA followed by Tukey’s post hoc test). 
 
 




Fig.32. Schematic representation of the Cued Fear Conditioning. Quantification of the freezing response in vehicle-
treated PWScrm+/p+ (WT) =13 and PWScrm+/p−mice (PWS) =10 or bumetanide-treated PWScrm+/p+ (WT) =7 and 
PWScrm+/p−mice (PWS) =11 in the Pre-cue (A) and Post-cue (B) fear conditioning test. (*P< 0.05, two-way ANOVA 
followed by Tukey’s post hoc test). 
 
3. PWScrm+/p−mice do not show significant anxiety and stereotypic behavior in the Open 
Field 
Next, we also assessed anxiety-like behavior in PWScrm+/p−mice in the open field, from the 
habituation of NOR (see protocol), to investigate about a possible contribution of NKCC1 
upregulation on anxiety disorders in PWS individuals. In particular, we evaluated the time spent in 
the center of the arena and the number of entries in the center of arena as an index of reduced 
anxiety levels showed by mice. We also analyzed general motor activity levels. No significant 
difference was found for number of entries and time spent in the center of arena between 
PWScrm+/p− and WT (Fig.33A and Fig.33B), independently of motor activity level measured as the 
travelled distance (Fig.33C). 
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Fig.33. Top= Schematic representation of the Open field (a) Quantification of the number of entries in the center of field 
in vehicle-treated PWScrm+/p+ (WT)=10 and PWScrm+/p− (PWS) =9 or bumetanide-treated PWScrm+/p+ (WT)=9 and 
PWScrm+/p− (PWS) =11 in open field (P >0,05, two-way ANOVA followed by Tukey’s post hoc test). (b) Quantification time 
in the center of field in vehicle-treated PWScrm+/p+ (WT)=11 and PWScrm+/p− (PWS) =9 or bumetanide-treated PWScrm+/p+ 
(WT)=9  and PWScrm+/p− (PWS) =8 in the open field. (P >0,05, two-way ANOVA followed by Tukey’s post hoc test). (c) 
Quantification of the distance travelled in PWScrm+/p+ (WT)=10  and PWScrm+/p− (PWS) =8  or bumetanide-treated 






4. PWScrm+/p− mice do not present any significant feature related to obsessive-compulsive 
disorders 
 
Next, we investigated whether defect of Cl- homeostasis of PWScrm+/p− are implicated in repetitive 
behaviors, important hallmarks linked to ASD, and obsessive-compulsive disorders showed in PWS 
individuals. To this aim, we performed diverse behavioral tests such as self-grooming, digging and 
marble burying. 
Self-grooming is a very complex innate behavior, characterized by the presence of a sequence of 
evolutionary conserved patterns. Rodents show frequently behavioral activities involving self-
grooming, which are important in hygiene maintenance and other physiologically important 
processes such as thermoregulation, social communication and de-arousal (JC Fentress, 1968 a,b; 
BM Spruijt et al 1988; BM Spruijt et al,1992;  ST Leonard et al, 2005; A Kalueff et al, 2010). However, 
self-grooming attitude can change during stressful states or in certain neuropsychiatric disorders, 
such as autism (JN Crawley, 2007; SE Ahmari et al 2013; A Roth et al,2013). Indeed, it represents a 
relevant aspect related to the neurobiology complexity, repetitive and sequential pattern of 
behavior (AM Graybiel et al, 2002; A Kalueff et al,2007; A Kalueff et al ,2010). 
Thus, we measured the total time and the number of episodes of self-grooming in PWScrm+/p- mice 
compared with controls (Fig.34A, B). We found no changes for self-grooming in presence of 
Snord116 deletion (Fig34A, B). In addition, we also evaluated the digging behavior in a new closed 
field and the marble burying test. Digging and marble burying has been strongly used to assess 
obsessive/compulsive behaviors and ASD-like behaviors in rodent models (DA Amodeo et al 2012; 
SL Andersen et al 2010; RM Deacon, 2006; SS Moy et al, 2014; ML Scattoni et al, 2008; JL Silverman 
et al, 2015; H Takeuchi et al,2002).  We found that the time spent and the number of episodes of 
digging were not statistically different between groups (Fig.35A, B). As well as, no differences we 
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found for the Marble burying test between groups (Fig.36). Finally, we also analyzed the number of 
wall rearing and twirling as index of stereotypic behavior. Again, we found no evidence of alterations 
of these behaviors in PWScrm+/p- compared to WT (Fig.37 and Fig.38). 
 
A  
                                      
                                  B 
Fig.34. Top= Schematic representation of the mice self-grooming. (A) Time spent in self-grooming and (B) number of 





                        A 
 
 
                          B 
 
Fig.35. Top= Schematic representation of the mice digging. (A) Time spent in digging and (B) number of dig bouts in 






Fig.36. Top= Schematic representation of the Marble burying. Quantification of % of Marble >2/3 buried in PWScrm+/p+  
(WT) =10  and PWScrm+/p- (PWS) =9. P>0,05, by t.test student. 
 
 
Fig.37. Top= Schematic representation of the Wall rearing. Quantification of number of Wall rearing in PWScrm+/p+ (WT) 




Fig.38. Top= Schematic representation of the Twirling. Quantification of number of Twirling in PWScrm+/p+ (WT) =11 and 
PWScrm+/p- (PWS) =9. P>0,05, by t.test student. 
 
5. Sociability is not significantly affected in mutant PWScrm+/p− mice 
 
In order to investigate on the implication of aberrant Cl- homeostasis in ASD-like behaviors (Ben-Ari, 
2017), which are present also in PWS individuals (Dykens EM et al, 2019), we focalized our attention 
on the sociability of PWScrm+/p− mice. In mutant PWScrm+/p- mice, we thus evaluated whether 
Snord116 paternal deletion affects sociability. To this aim, we performed two tests strictly related 
to sociability, the Male-Female interaction test (Fig.39) and three-chamber test (Fig.40) 
(Kaidanovich-Beilin. O et al, 2011; Ricceri et al, 2016).  
First, we performed a Male-Female interaction test (Fig.39). Mice are usually very active to interact 
with each other during social interaction, and they are commonly show sniffing of anogenital region, 
head, and of the rest of their bodies, and dedicate time in touching each other with a reciprocal 
following (mostly observed in male versus female mice). 
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In particular, we measured the time spent in sniffing as index of the social approach in tested male 
mice vs a never-met-female mouse. Results have confirmed no significant differences in sociability 
in PWScrm+/p- compared to controls (Fig.39). 
Next, in the three-chamber test, we assessed the sociability index (Fig.40A,B), in terms of the social 
approach of the tested mice with a never-met-intruder in comparison to an object; and the social 
novelty  (Fig.40C,D),  as a social approach of tested mice with a novel never-met-intruder in 
comparison to the already met intruder. PWScrm+/p- mice did not show any significant alteration in 
sociability index respect to WT, for time spent in compartment and sniffing of a never-met-intruder 
compared to an object (Fig.40A,B). No differences between groups were present also in the social 
novelty for time spent in compartment and sniffing of a novel never-met-intruder compared to an 
already met intruder (Fig.40C,D). 
 
 
Fig.39. Top= Schematic representation of the male-female interaction. Time spent of a male mouse versus a never 






Fig.40. Top= Schematic representation of the Three chamber test for social index. (A) Discrimination index of time spent 
in compartment of never met mouse versus an object, in PWScrm+/p+ (WT) =8 and PWScrm+/p- (PWS)=7. P>0,05, by t.test 
student. (B) Discrimination index of time spent in sniffing of never met mouse versus an object, in PWScrm+/p+ (WT) =8 
and PWScrm+/p- (PWS)=7. P>0,05, by t.test student. Top= Schematic representation of the Three chamber test for social 
novelty. (C) Discrimination index of time spent in compartment of never met mouse versus a familiar mouse, in 
PWScrm+/p+ (WT) =8 and PWScrm+/p- (PWS)=7. P>0,05, by t.test student. (D) Discrimination index of time spent in sniffing 





6. PWScrm+/p− mice show an increase of pain sensitivity in presence of a thermal stimulus  
 
Finally, we assessed the pain sensitivity to an acute thermal stimulus in PWScrm+/p− using a hot plate 
platform kept at constant temperature of 52°C. We measured the response in terms of latency to 
lick the paws from the hot plate, as sign of pain sensitivity, applying a cut-off latency of 30 seconds. 
Interestingly we found that PWScrm+/p− present significantly a greater sensitivity to pain compared 





Fig.41. Top= Schematic representation of the Hot plate test. Quantification of pain sensitivity in PWScrm+/p+ (WT) =16 





7. PWScrm+/p- show a reduced shortening of the circadian period and an increase of activity 
in DD, rescued by bumetanide chronic treatment.  
 
Sleep disorders have been well characterized in both PWS individuals and PWScrm+/p− mutated mice 
(Lassi et al, 2016), while no evidences are reported on circadian rhythms. Snord116 gene deletion 
has been associated to different clock gene expression of Clock, Cry1, Cry2, Per1 and Per2, enhancing 
circadian zeitgebers (Powell et al, 2013). Therefore, we decided to assess the circadian clock of 
PWScrm+/p−mice using running wheels in Light-Dark (LD) and Dark-Dark (DD) cycle, used to evaluate 
the endogenous circadian period also called as the free running period.  
Thus, to characterize the circadian period and the impact of Cl- homeostasis in the presence of 
Snord116 deletion, we tested PWScrm+/p- and control mice treated with vehicle or bumetanide 
(2mg/kg body weight in drinking water) using running wheels in their home-cages during 24 hr for 
20 total days (10 days of LD cycle followed by 10 days of constant darkness), without any 
interruptions. 
The circadian period of each mouse was derived from wheel running activity. We observed that 
PWScrm+/p- mice showed a significant lengthening of their internal clock in DD condition compared 
to the WT mice, completely rescued by bumetanide treatment (Fig.42C). Conversely, we did not find 
any changes during LD cycle among groups (Fig.42B).  
In addition, we also evaluated the time devoted to the behavioral activity, expressed as the length 
of the segment of the daily activity (alpha) during LD and DD conditions.  
Interestingly, we reported a significant increase of alpha activity in PWScrm+/p- compared to WT, 
reduced by bumetanide treatment. 
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However, bumetanide in WT significantly strengthened the difference with PWScrm+/p- treated with 
vehicle or bumetanide during constant darkness (Fig.42E). Conversely, we did not observe any 
difference of alpha activity among groups during LD condition (Fig.42D). 
 
 





Fig.42. (A) Representative actograms of wheel-running activity under light-dark (LD) conditions, followed by constant 
darkness (DD). Periods of light and dark are respectively indicated by yellow and white panels. (B) Quantification of 
circadian period in LD vehicle-treated PWScrm+/p+ (WT)=7 and PWScrm+/p− (PWS) =4 or bumetanide-treated PWScrm+/p+ 
(WT)=6 and PWScrm+/p− (PWS) =4. P>0,05, two-way ANOVA followed by Tukey’s post hoc test.  (C) Quantification of 
circadian period in DD vehicle-treated PWScrm+/p+ (WT)=7 and PWScrm+/p− (PWS) =4 or bumetanide-treated PWScrm+/p+ 
(WT)=7 and PWScrm+/p− (PWS) =4.*P<0,05, two-way ANOVA followed by Tukey’s post hoc test. (D) Quantification of 
alpha activity in LD vehicle-treated PWScrm+/p+ (WT)=7 and PWScrm+/p− (PWS) =4 or bumetanide-treated PWScrm+/p+ 
(WT)=7 and PWScrm+/p− (PWS) =4. P>0,05, two-way ANOVA followed by Tukey’s post hoc test. (E) Quantification of alpha 
activity in DD vehicle-treated PWScrm+/p+ (WT)=7 and PWScrm+/p− (PWS) =4 or bumetanide-treated PWScrm+/p+ (WT)=7 






















1. The role of Cl- homeostasis in sleep disorder of DS 
 
In this study, we have explored the sleep and EEG abnormalities, and the implication of Cl- 
mechanisms in a mouse model of DS, which could be translated to the human pathology. To this 
aim, we selected the strain of Ts65Dn mice, which are the most studied and widely used model, 
characterized by NKCC1 upregulation in hippocampus and cortex. This has been linked to 
depolarizing and possibly excitatory vs hyperpolarizing and inhibitory GABAergic transmission   in 
Ts65Dn animals (Deidda et al, 2015).  
Ts65Dn mice recapitulate many features of DS showing impairment in neuronal development 
(Belichenko et al., 2004; Chakrabarti et al., 2010; Chakrabarti et al., 2007; Contestabile et al., 2010; 
Contestabile et al., 2007), defects of synaptic plasticity (Contestabile et al., 2013; Costa & Grybko, 
2005; Kleschevnikov et al, 2004; Siarey et al., 1999; Siarey et al., 1997), impaired hippocampus-
dependent memory functions (Contestabile et al., 2013; Costa et al., 2008; Fernandez et al., 2007; 
Reeves et al., 1995), hyperactivity (Escorihuela et al., 1995; Reeves et al., 1995; Sago et al., 2000) 
and sleep disorders (Colas et al., 2008). Previously, sleep pattern in Ts65Dn mice was poorly 
characterized by just one study that had been conducted by Colas et al. Nevertheless, this study 
highlighted major sleep abnormalities, including increased wakefulness, decreased NREM sleep, 
increased theta power during NREM and REM sleep and a delayed, but increased sleep rebound 
after sleep deprivation (Colas et, al 2008).  
Our study extends the understanding of sleep physiology in Ts65Dn mice, including more detailed 




In particular, we found an increase of wakefulness, and a reduction of NREM sleep before and after 
SD, but no abnormalities in REM phase in Ts65Dn mice. However, these mice present with a 
reduction of delta waves in REM at baseline and NREM before and after SD together with an increase 
of theta power density before and after SD. Interestingly, bumetanide treatment exerted on Ts65Dn 
mice an effect on power density of delta and theta waves, improving the quality of sleep in both 
NREM and REM sleep phases before and after SD, without any changes in WT. Moreover, 
bumetanide does not give rise to significant variations on epochs amounts of NREM and REM 
suggesting that the major architecture of sleep is not compromised by the GABAergic transmission. 
However, important alterations regarding the quality of sleep were evident, and bumetanide has 
shown to be able to decrease the abnormal wakefulness in Ts65Dn at baseline. Accordingly, our 
results displayed that bumetanide could have a potential effect to improve sleep quality in DS 
individuals.  
Spectral power of theta was also found increased and correlated with a decline of cognitive function 
in the Parkinson Disease (Cozac et al, 2016), so it may represent a possible implication in cognitive 
alterations and the age-related neurodegeneration associated with DS (Lockrow at al, 2012). 
Moreover, the balance of inhibitory and excitatory septohippocampal inputs affects theta 
oscillations, which are mostly expressed in hippocampal networks (Buzsaki, 2002). In this context, 
the increased EEG theta power that we describe in Ts65Dn mice may be the result of increased 
synaptic connectivity/activity at hippocampus-network level or could be the result of the 
engagement of further oscillating networks, either directly or via septohippocampal networks (Colas 
et al, 2008). So, our results showing the increase of theta waves in Ts65Dn mice may be linked to a 
dysregulation of Cl- homeostasis and consequent GABAergic neurotransmission within the 
hippocampus, as found in (Deidda et al, 2015). In support of this, GABAergic transmission has been 
implicated of in theta oscillations (Buzsaki, 2002) by experiments reporting elimination of theta in 
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terms of rhythm generation and current generation through, blocked or potentiation of GABAA 
receptor signaling during picrotoxin-induced epilepsy or pentobarbital anesthesia, (Vanderwolf, 
1988).  On the other hand, the effect that we described on theta power could also be linked to App 
gene triplication, which is present in Ts65Dn mice (and individuals with DS). (Colas et al, 2008). 
Indeed, DS studies on humans, mouse models and induced human pluripotent stem cells have 
shown the presence of the triplication for the Amyloid Precursor Protein (APP) gene, which 
determines an increase of Aβ brain levels (Wiseman FK et al 2015). In particular, App plays a role in 
regulating synaptic function and vesicular axonal transport (Kamal et al, 2001, Kamenetz et al, 2003) 
and its overexpression is involved in disruption of the retrograde transport of NGF, at level of septal 
cholinergic neurons in the Ts65Dn model. This alteration is related to an augmentation of theta 
power in Ts65Dn mice at 3 months of age (Salehi et al, 2006).  
Another behavioral characteristic already described in Ts65Dn mice (and in individuals with DS) is 
an augmentation of motor activity. This is characterized by a greater exploratory behavior compared 
to controls, mainly during the dark period (Coussons-Read and Crnic, 1996, Martinez-Cue et al., 
2002, Deidda et al 2015). Our data agree with the last studies showing an increase of motor activity 
and wakefulness. Interestingly, bumetanide treatment caused a reduction of activity, suggesting a 
regulation of motor behavior promoted by GABAergic transmission. A possible hypothesis to 
conciliate these data may be that increased wake and activity could be a compensatory mechanism 
to defective information processing, as well as, the increase of theta power (Colas et al, 2008). We 
also characterized body temperature, which represents a main regulator of sleep that follow the 
circadian rhythms. In particular, a decrease of temperature is present during the sleep period, 
whereas an increase coincides with the awakening (Parmeggiani et al, 1971; Parmeggiani, 1980; 
Parmeggiani, 1987). Interestingly, changes in body temperature have been associated with insomnia 
and occur in individuals following sleep deprivation, when subjects become more vulnerable to heat 
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loss, with less ability to warm themselves to a comfortable temperature (Landic CA et al,1998; 
Masanobu.H et al, 2017). Interestingly, we showed a significantly lower body temperature in Ts65Dn 
mice compared to controls. More investigation will be needed to investigate whether this difference 
in body temperature between Ts65Dn mice and WT has some influence on their sleep pattern.  
Considering the relationship between eating activity and sleep patterns reported in literature, we 
also evaluated food intake in Ts65Dn mice. In particular, independent studies on humans have 
reported that short sleepers have higher energy intakes compared to normal sleepers (Imaki M et 
al, 2002; Weiss et al, 2010). Further studies will also be required to investigate whether the increase 
of food intake that we describe here in Ts65Dn mice is correlated to sleep abnormalities in these 
mice intake. 
 
Although sleep disturbances are among the health issues mostly affecting the quality of life of 
people with DS not many studies have been conducted in DS individuals so far. This is mainly due to 
technical difficulties of people with DS in cooperating during EEG recordings and the presence of 
sleep apnea. For this reason, correlation with our results reported in Ts65Dn mice on the human 
condition is somehow incomplete. Nevertheless, there is evidence of an increase of wakefulness 
and hyperactivity in people with DS, which parallels our results. On the other hand, an augmentation 
of theta power seems to be not reported in DS humans, even if specific investigations have never 
been performed. Moreover, human studies, using appropriate age-matched controls, and 
characterized by careful spectral analysis across different brain regions, are needed. This is a crucial 
issue also when considering that sleep disturbances may be involved in the poor cognitive 
performance in DS people and the clinical evolution of DS, characterized by early dementia in the 
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elderly people (Colas et al 2008). In this perspective, the use of bumetanide as a therapy to improve 
sleep quality could also benefit the lives of DS people. 
 
2. The role of Cl- homeostasis in behaviors and circadian rhythms of PWS 
 
Several studies reported in the literature indicates that an aberrant Cl- homeostasis, caused by 
imbalance in NKCC1 vs KCC2 activity and/or expression, is involved in a large number of neurological 
disorders.  In addition, NKCC1 inhibition promoted by bumetanide treatment appears to be an 
effective therapeutic strategy to improve behavioral alterations in many animal models of these 
neurological disorders (Ben-Ari, 2017; Schulte et al, 2018). Notably, benefits and efficacy of 
bumetanide treatment have been also showed in several clinical trials and case studies performed 
on patients (Ben-Ari, 2017).  
 
Cognitive impairment, anxiety, obsessive-compulsive and ASD symptoms reported in PWS have 
never found explanation in a specific alteration of some molecular mechanisms. However, abnormal 
GABA metabolism and GABAA receptors in PWS were reported in literature (Lucignani G et al, 2004; 
Rice L.J et al 2016). These deficits were related to abnormal expression of GABAA receptor subunit 
genes (GABRB3, GABRA5, and GABRG3), present on the PWS/AS chromosomal region (15q11–13) 
(Lucignani G et al, 2004). These supportive evidences for a GABA dysfunction have encouraged the 
hypothesis of a possible involvement of GABA in behavioral alterations of PWS. Here, we completed 
these investigations by addressing the role Cl- homeostasis in PWS, prompted by its in several other 
neurodevelopmental disorders (Ben-Ari, 2017). We conducted our experiments on mutant 
PWSCrm+p- characterized by a very short paternal deletion involving Snord116 gene, mostly 
implicated in the phenotypic manifestations of PWS (Bieth E et al, 2015).  
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Interestingly, we reported the imbalance of NKCC1 levels specifically for the hippocampus of 
PWSCrm+p- mice compared to controls, without any changes in the hypothalamus, SCN and the 
prefrontal cortex. Conversely, KCC2 expression did not significantly modify in the hippocampus of 
mutant PWSCrm+p- mice.  
As demonstrated for other neurodevelopmental disorders (e.g., Down syndrome, autism spectrum 
disorders) (Ben-Ari, 2017) this is suggestive of the presence of a depolarizing and possibly excitatory 
GABAergic transmission (rather than hyperpolarizing and inhibitory). Nevertheless, further 
electrophysiological recordings are needed in the future to directly prove this hypothesis. 
Moreover, Snord116 is a cluster of small nucleolar/noncoding RNAs (snoRNAs), mainly expressed in 
the brain, which are involved in the control of the expression of other small nucleolar RNAs (Sahoo 
et al, 2008), and may influence the transcription of other genes. So, our results also suggest that 
probably Snord116 could also regulate the expression of NKCC1 through mechanisms that need to 
be explored.  Whether these expression changes are a primary event due to the imprinting 
mechanisms of Snord116 related to PWS or a secondary response to other modifications is yet to 
be established.  
Next, we characterized behavior that had been previously shown to be affected by impaired 
GABAergic transmission and/or Cl- homeostasis imbalance (Ben-Ari, 2017). In particular, we focused 
on long-term memory, anxiety, pain sensitivity, and other behaviors linked to obsessive/compulsive 
disorders and ASD in PWScrm+/p- mice.  
The absence of anxiety, obsessive/compulsive and ASD behaviors that we found in PWSCrm+p- mice 
has evidenced that Snord116 deletion and GABAergic transmission may not be correlated with these 
symptoms showed in PWS people. 
On the other hand, we did report the presence of cognitive impairments in the long-term memory 
of PWSCrm+p- mice. Notably, the cognitive impairments, completely rescued by bumetanide chronic 
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treatment, highlighting the implication of abnormal regulation of Cl- homeostasis and GABAergic 
transmission in cognitive deficits of PWS. Moreover, we found an increase of pain sensitivity in 
PWSCrm+p- mice, which could be associated with defects in the thermoregulatory system. Indeed, 
these mice are characterized by a higher peripheral temperature compared to controls (Lassi et al, 
2016), and variations of skin temperature are reported to have an important effect on the latency 
of behavioral responses during studies of nociception. In support of our results, higher temperatures 
have been correlated into a decrease in withdrawal latency (Bitar Ne et al, 2014). 
 
Experiments to evaluate circadian clock in the PWS have never been conducted until now. However, 
individuals with PWS and PWSCrm+p- mice model have reported defect in the thermoregulation and 
abnormalities of sleep/wake cycles (Richdale et al, 1999; Ince E et al, 2005; Gillett E and Iris A. Perez, 
2016; Lassi et al,2016), which could be related to a circadian rhythm dysregulation. Moreover, 
GABAergic signaling and mechanisms of Cl- homeostasis have been recently reported to be involved 
in the regulation of state plasticity in SCN network for maintaining behavioral responses to seasonal 
change (Rohr KE, 2019). For these reasons, we also executed circadian rhythm studies in mutant 
PWSCrm+p- and investigated on a possible contribution of an aberrant GABAergic transmission. 
Peculiarly, we observed that PWScrm+/p- mice have an elongation of their internal clock in DD 
condition compared to controls, completely rescued by bumetanide treatment. In contrast, we did 
not find any changes during LD cycle. In addition, we also evaluated the time devoted to behavioral 
activity alpha during LD and DD conditions, showing an increase of alpha activity in mutant 
PWScrm+/p- mice, reduced by bumetanide treatment. Altogether, these results indicate that cation 
Cl− cotransporters, NKCC1, but also KCC2, could represent promising targets for therapeutic 
interventions aimed at ameliorating the cognitive dysfunctions or disorders related to circadian 
clock of individuals with PWS though the modulation of GABAAR signaling. Interestingly, beside the 
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NKCC1 inhibitor bumetanide, compounds able to increase KCC2 activity/expression have been 
recently described (Tillman L and Zhang J, 2019). 
Here, we proposed a pharmacological treatment using bumetanide, an FDA-approved drug, for a 
disease linked to imprinting defects. We chose to use bumetanide because it has a strong potential 
to be rapidly translated as a safe therapeutic approach for clinical trials in PWS individuals. 
Conversely, new developed molecules (Braudeau, J. et al. 2011) need to have further evaluations 
for factors as safety, tolerability and pharmacokinetics (e.g., trials NCT01436955, NCT01684891 and 
NCT01667367 listed at http://clinicaltrials.gov/). In fact, bumetanide has a long clinical history as a 
diuretic in both acute and chronic (lifelong) treatments (Ward, O.C. & Lam, L.K 1977, Maa et al, 
2011). Moreover, bumetanide has just minor side effects such as the manifestation of a mild 
hypokalemia. Nevertheless, this can be addressed by a specific dietary supplementation. 
Furthermore, bumetanide did not show aversive effects during clinical trials in children with autism 
(trial NCT01078714, http://clinicaltrials.gov/) (Lemonnier, E. et al, 2012) (Lemmonier et al, 2017; 
James BJ.et al, 2019).   
 
Different studies have reported that bumetanide is able to reach the brain (Li, Y. et al 2011, Cleary, 
R.T. et al, 2013 Deidda et al ,2015), even if its brain penetration may not be optimal (Puskarjov M et 
al 2014). Our results, together with results of the systemic effects of bumetanide to treat other 
disorders related to the brain (Dzhala et al, 2005 Sipilä et al, 2006; Kahle et al, 2009; Mazarati et al, 
2009; Edwards et al, 2010; Lemonnier & Ben-Ari et al 2010; Lemonnier,  et al, 2012;  Hadjikhani et 
al, 2013;  Lemonnier et al, 2013; Tyzio et al 2014)  strengthen these evidences. The dose of 0.2 mg 
kg−1 used during chronic injections here was chosen on the basis of previous studies on rodents 
(Dzhala et al. 2005; Mares, 2009; Mazarati et al, 2009; Brandt et al 2010; Wang & Kriegstein, 2011; 
Deidda et al, 2015). While, the dose 2mg kg-1 for drinking water was conducted based on a previous 
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study showed in Tyzio et al, 2014. However, the dose that is used in mice is higher than the normal 
therapeutic range for humans (total daily dose, 0.5–2 mg; maximum daily dose, 10 mg) 
(http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018225s024lbl.pdf; 2008). This was 
justified by the fast-metabolic rate of bumetanide in rodents (Pentikäinen, et al 1977; Ostergaard 
et al, 1972, Löscher, et al, 2013). Moreover, the use of this dosage is also supported by the 
encouraging results of other studies for the treatment of autism conducted with dosages similar to 
those described before for patients and animal models (Lemonnier et al, 2012; Lemonnier & Ben-
Ari, 2010).  
To conclude, our data describe the first and innovative pharmacological approach for PWS, with a 
safe, FDA-approved drug that can be readily translatable directly on people with PWS. We adopted 
a strategy of ‘drug repurposing’ (Strittmatter, 2014) in order to reduce the high costs and long time 
periods, considering the long period between testing new therapeutic approaches in animal models 
and the commercialization of newly developed drugs.  
Finally, our data on bumetanide treatment of adult animals encourage the possibility to be able to 
ameliorate cognitive symptoms and circadian alterations that result from imprinting defects 











Animals and treatment (DS)  
All animal procedures were approved by IIT licensing in compliance with the Italian Ministry of 
Health (D.Lgs 26/2014) and EU guidelines (Directive 2010/63/EU). A veterinarian was employed to 
maintain the health and comfort of the animals. Mice were housed in filtered cages in a 
temperature-controlled room with a 12:12 hour dark/light cycle and with ad libitum access to water 
and food. All efforts were made to minimize animal suffering and use the lowest possible number 
of animals required to produce statistical relevant results, according to the “3Rs concept”. In this 
study, we used Ts65Dn mice (R.H Reeves et al, 1995) generated by repeated backcross of Ts65Dn 
female to C57BL/6JEi x C3SnHeSnJ (B6EiC3) F1 males (Jackson Laboratories). Ts65Dn mice were 
genotyped by PCR as previously described (A Duchon et al, 2011). Animals aged between 3-4 months 
were used for experiments. Only males were used for sleep experiments. Ts65Dn and WT 
littermates were randomly assigned to bumetanide (Sigma; 2 mg/kg body weight, as described in 
Tyzio et al, 2014) or vehicle groups (2% DMSO in saline) in drinking water and treated chronically 
after 4 days from surgery for 4 days. We used bumetanide treatment in drinking water to allow a 
constant daily assumption of bumetanide to monitor its effect on the sleep parameters.  
 
Telemetry system  
Sleep was monitored by using a telemetry system. Telemetry is a wireless monitoring system that 
allows monitoring sleep. This procedure is feasible in mice using a radio-telemetry system for 
recording heart rate, electromagnetic phenomena (EEG) and electromyogram (EMG) (Data Sciences 
Int, St Paul, Minnesota 55126- 6164, USA - see internet website: 
http://www.datasci.com/products/implantable_telemetry/mouse.asp). The system includes a 
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miniature telemetric instrument (the transmitter) that contains a battery to which two pairs of 
electrodes (DSI physiotel TL11M-F20-EET) are connected. The battery allows the monitoring of the 
activity of two biopotentials for 6 weeks without interruption. This miniature plant is capable of 
measuring 2.5 mV peak to peak, but also overall mouse activity and body temperature. Digitized 
signals are transmitted from this system through radio frequencies to the receiver located under 
the cage. The receiver then transmits the data to the computer where a Dataquest Data Acquisition 
System allows you to view and then analyze the data. This system will allow the measurement of 
EEG, EMG, motor activity and temperature for long periods without the need of any animal 
restriction. For each mouse, a daily food intake was calculated. Food intake was adjusted for body 
weight and expressed as “food intake index”. 
 
Surgery 
We used 3-4 months adult mice of at least 20 grams weight. Before the implant, all the mice were 
anesthetized and therefore all surgical procedures were performed in animals subjected to total 
anesthesia. Isofluorane by means of a vaporizer (Dose: - Induction (chamber): 4.0 - 5.0 vol. % 
Isofluorane - Maintenance (mask): 1.5 - 2.0 vol. % Isofluorane). The level of anesthesia was 
constantly monitored by the nosocomial reflection at the tail and / or the paw level and the corneal 
reflection. Body temperature was maintained through the use of a thermal blanket. After 
trichotomy and disinfection, with the animal in general anesthesia, animals were carved and 
subcutaneously cut along the median line of approximately 2 cm for the introduction of the 
miniature transmitter into the peritoneal cavity. The transmitter wireless containing the electrodes 
was placed cranially. A sterile catheter was passed under the skin to reach the back of the neck. The 
cables passed through the hose and hence the tube was removed leaving the cables at 
subcutaneous level. In some cases of surgery, we put the transmitter under the skin and therefore 
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no abdominal wall incision was made. At this point, through a central incision on the head, the 
electrodes were positioned over the right hemisphere (approximately 2 mm from the central line 
and about 1 mm from the bramble) and left hemisphere (about 3 mm from the central line and 
about 1 mm from the lambda). The electrodes were fixed using miniaturized screws or placed in a 
special hole and then covered with acrylic of the type used in dental procedures. After positioning 
the pair of electrodes for the EEG, the electrodes were positioned for the detection of muscle 
activity. In this case, the electrodes were inserted into the neck muscle through the use of a needle. 
The same electrodes were fixed to the muscle through 1-2 suture points. Then, the incision on the 
scalp and neck were closed and sutured with absorbable material (eg Dexon II, 3-0, Vicryl, 2-0). For 
post-operative recovery, some analgesics (eg ketorolac or carprofen) were used.  
 
Deprivation of sleep  
For short Sleep Deprivation (6hrs), mice were kept awake by the experimenter's intervention. In 
particular, an air jet or a brush was used by the experimenter any time that the animal had a sleeping 
posture. Various objects were introduced in the mouse cages to stimulate their curiosity, without 
inducing stress. The goal of this method is to get a sleep deprivation with the least stress since stress 
modifies the fundamental sleep properties. 
 
Statistical analysis 
The statistical tests were performed with MATLAB and GraphPad Prism 8.3. Two-way mixed 
analyses of variance (ANOVAs) (Genotype × Treatment) were run temperature, activity and food 
intake in order to compare WT with Ts65Dn mice across light and dark phases. For all sleep 
parameters and the power spectral analysis of NREM and REM the effects of two parameters 
(genotype and treatment) were decomposed using two-tailed t-tests as described in Lassi et al, 2016 
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and Diessler et al 2017. Outliers were excluded only from the final pool of data by a Grubb’s test run 
iteratively until no outliers were found. 
 
Animals and treatment (PWS) 
All animal procedures were approved by IIT licensing in compliance with the Italian Ministry of 
Health (D. Lgs 26/2014) and EU guidelines (Directive 2010/63/EU). A veterinarian was employed to 
maintain the health and comfort of the animals. Mice were housed in filtered cages in a 
temperature-controlled room with a 12:12 hour dark/light cycle and with ad libitum access to water 
and food. All efforts were made to minimize animal suffering and use the lowest possible number 
of animals required to produce statistical relevant results, according to the “3Rs concept”. In this 
study, we investigated mice carrying a deletion of the PWS critical region (PWScrm+/p-) including 
Snord116 and IPW exons compared to WT controls (PWScrm+/p+). In the Istituto Italiano di Tecnologia 
(IIT), mice were bred and maintained through paternal inheritance on a C57BL/6J background. Male 
mice of 3-4 months old were tested for all behavioral tests. WT controls female mice of 3-4 months 
old were used just for male-female interaction test. 
PWScrm+/p− and WT littermates were untreated or randomly assigned to bumetanide (Sigma; 0.2 
mg/kg body weight for injection or administration in water solution 2mg/ kg body) or vehicle groups 
(2% DMSO in saline) for cognitive and circadian rhythms investigations.   
 
Protein extraction  
For total protein extraction, hippocampal and cortical samples were homogenized in RIPA buffer 
(1% NP40, 0.5% deoxycholic acid, 0.1% SDS, 150 mM NaCl, 1 mM EDTA, 50 mM Tris, pH 7.4) 
containing 1 mM PMSF, 10 mM NaF, 2 mM sodium orthovanadate and 1% (v/v) protease and 
phosphatase inhibitor cocktail (Sigma). The samples were clarified by centrifugation at 20,000g, and 
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the protein concentration was determined using a Bicinchoninic Acid Assay (BCA) kit (Pierce). 
Western blotting For immunoblot analysis, equal amounts of protein were run on 4–12% Bis-Tris 
NuPAGE (Invitrogen) or Criterion-XT (Bio-Rad) gels and transferred onto nitrocellulose membranes 
(GE Healthcare). Membranes were probed with mouse anti-NKCC1 (clone T4, Developmental 
Studies Hybridoma Bank; 1:4,000), rabbit anti-KCC2 (Millipore, catalog no. 07-432; 1:4,000), rabbit 
anti β-actin (Sigma, catalog no. A2066; 1:10,000), mouse anti-Na+/K+-ATPase (clone C464.6, 
Millipore, catalog no. 05-369; 1:2,000), mouse anti-APP (clone 22C11, Millipore, catalog no. 
MAB248; 1:2,000), followed by HRP-conjugated secondary antibodies goat antirabbit and goat anti-
mouse (Thermo Scientific, catalog nos. 31460 and 31430, respectively; 1:5,000). 
Chemiluminescence signals were digitally acquired on an LAS 4000 Mini Imaging System (GE 
Healthcare), and the band intensities were quantified using ImageQuant software (GE Healthcare). 
In some experiments, membranes were stripped and reprobed with a second antibody. The 
specificity of antibodies to NKCC1 and KCC2 was verified on brain samples from NKCC1- and KCC2-
deficient mice, respectively (kind gift of Dr. K. Kaila, University of Helsinki;).  
 
Behavioral testing  
Mice were tested after 1 week of treatment with vehicle, DMSO or bumetanide (0.2 mg*kg-1 i.p.). 
The battery of tests was run over a total period of 3 weeks (behavioral tests for PWScrm+/p- and WT 
littermates in the following order NOR, OL, Fear conditioning). During the days of behavioral testing, 
animals were treated daily with the drug, with tests beginning 1 h after injection. The tasks were 
video-recorded and then analyzed manually by a blind operator. After each trial or experiment, the 
diverse apparatus and objects were cleaned with 70% ethanol.  
Next another cohort of mice, not subjected to any treatment, was used to investigate on ASD, pain 
sensitivity and obsessive/compulsive disorders in PWScrm+/p- mice. 
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Novel object recognition test (NOR)  
The NOR test was conducted in a gray acrylic arena (44 × 44 cm). On the day before the NOR test, 
mice were allowed to become habituated to the apparatus by freely exploring the open arena for 
10 min. NOR is based on the preference of mice for a novel object versus a familiar object when they 
are allowed to explore freely. The objects used were different in shape, color, size and material. 
During the acquisition sessions, three different objects were placed into the arena, and the mice 
were allowed to explore for 10 min. Object preference was evaluated during these sessions. Testing 
occurred 24 h later in the same arena. In the test, one of the objects used in the acquisition session 
was replaced by a novel object, and mice were allowed to explore freely for 10 min. The objects 
were counterbalanced between the sessions and were cleaned with 70% ethanol after each trial. 
Exploratory behavior toward an object was defined as direct contact with the object by the animal's 
mouth, nose or paws or as an instance when the animal approached the object so that its nose was 
within 1 cm of the object. Any indirect or accidental contact with the objects was not included in 
the scoring. The time spent exploring each object, expressed as a percentage of the total exploration 
time, was measured for each trial. The discrimination index was calculated as the difference 
between the percentage of time spent investigating the novel object and that of time spent 
investigating the familiar objects: Discrimination Index = ((Novel Object Exploration Time/Total 
Exploration Time) × 100) − ((Familiar Object Exploration Time/Total Exploration Time) × 100). 
Experiments of Open field, Twirling and Wall rearing were derived from the videos recorded during 
the habituation phase of NOR. 
 
Object location test (OL)  
The OL test evaluates spatial memory by measuring the ability of mice to recognize the new location 
of a familiar object on the basis of the available extra-maze cues. The test was conducted in a gray 
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acrylic arena (44 × 44 cm). Mice were habituated to the chamber for 15 min on the day before 
testing. The next day, mice were exposed to two identical objects for 15 min during the acquisition 
phase. Object preference was evaluated during this session. Testing occurred 24 h later in the same 
arena. During the trial session, one of the objects was moved to a novel location, and mice were 
allowed to explore the objects for 15 min. The objects and the arena were cleaned with 70% ethanol 
after each trial. The time mice spent exploring each object was measured. ‘Exploration’ was defined 
as any investigative behavior toward (i.e., head orientation, sniffing occurring within <1.0 cm) or 
deliberate contact with an object. A discrimination index was calculated as the percentage of time 
spent investigating the object in the new location minus the percentage of time spent investigating 
the object in the old location: Discrimination Index = ((New Object Location Exploration Time/Total 
Exploration Time) × 100) − ((Old Object Location Exploration Time/Total Exploration Time) × 100). 
 
Fear conditioning (FC) 
Delay contextual and cued fear conditioning was conducted using an automated fear-conditioning 
chamber (Med Associates, St Albans, VT, USA). The conditioning chamber was interfaced to a PC 
installed with VideoFreeze software (version 1.12.0.0, Med Associates) and enclosed in a sound-
attenuating cubicle. Training consisted of a 2-min acclimation period followed by three tone-shock 
(CS–US) pairings tone-shock (CS–US) pairings (80 dB tone, duration 30-s; 0.5 mA footshock, duration 
1 s; intershock interval 90-s) and a 2.5-min period, during which no stimuli were presented. The 
environment was well lit (∼100 lx), with a stainless steel grid floor. A 5-min test of contextual fear 
conditioning was performed 24-hr after training, in the absence of the tone and footshock, but in 
the presence of 100 lx overhead lighting, and  an identical  context to that used on the training day. 
Cued fear conditioning, conducted 48-hr after training,  mice were moved to a new environmental 
context (black chamber with plastic gray floor and vanilla odor). Overhead lighting was turned off. 
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The cued test consisted of a 3-min acclimation period followed by a 3-min presentation of the tone 
CS and a 90-s exploration period. The freezing behavior was scored by a trained operator blinded to 
the experimental groups. 
 
Three-chamber test 
The test evaluates the social approach of the tested mouse vs a never-met-intruder in comparison 
to an object (sociability) or vs a novel never-met-intruder in comparison to the already met intruder 
(social novelty), and it was performed similarly to what previously described in mouse models of 
autism. The three-chamber apparatus consists in a rectangle, three-chambered box of grey acrylic. 
The chambers are accessible by rectangle openings with sliding doors. In the first 10 minutes 
(habituation) the tested mouse was free to explore the apparatus containing two inverted stainless-
steel wire pencil cups (one in each of the two side chambers), with a weighted plastic cup on the 
top of them, to prevent the mouse climbing on the top. Then, the tested mouse was briefly confined 
in the center chamber while a never-met-intruder (previously habituated to the apparatus) was 
placed in one of the side chambers, under the pencil cup. For the following 10 minutes (sociability 
test), the tested mouse was allowed to explore all the three chambers. Then, the tested mouse was 
again briefly confined in the center chamber while a novel never-met-intruder (previously 
habituated to the apparatus) was placed in the other side chamber under the pencil cup. Thus, for 
the following 10 minutes (social novelty test) the tested mouse was allowed to explore all the three 
chambers. The time spent exploring the object or the intruder was calculated by measuring the 
second when the mice showed investigative behavior (i.e., head orientation, sniffing occurring 
within < 1.0 cm) or time spent in compartment. The sociability index was calculated as the difference 
between the time spent investigating the never-met-intruder and the time spent investigating the 
familiar object divided by the total exploration time: sociability index = (never met intruder 
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exploration time - object exploration time)/( never met intruder exploration time + object 
exploration time). The social novelty index was calculated as the difference between the time spent 
investigating the novel never-met-intruder and the time spent investigating the already met 
intruder divided by the total exploration time: social novelty index = (novel never met intruder 
exploration time - already met intruder exploration time) /(novel never met intruder exploration 
time + already met intruder exploration time). 
 
Male-Female interaction 
The test evaluates the social approach, based on male-female interaction of the tested male mouse 
vs a never-met-female mouse. For the habituation, the tested mouse was placed singularly in a cage 
(26 cm × 48 cm × 20 cm). It was performed in a similar way to that previously described for mouse 
models of ASD (E Drapeau et al, 2018). After 5 minutes, an unfamiliar C57BL/6J female mouse was 
placed into the home-cage of the isolated male mouse, and behavior was recorded for a 5-min test 
session. The time spent interacting with the female intruder was calculated by measuring the second 
when the mice showed any of the following interacting behavior: anogenital sniffing, body sniffing, 
head sniffing, following and mounting. Digging and grooming analysis were executed during the 
habituation. 
Experiments of grooming and digging were derived from the videos of the habituation of Male-
Female interaction protocol. 
 
Hot Plate test 
The response to an acute thermal stimulus was assessed. In particular, the experimenter held the 
mouse and gently placed the paws of the animal on the surface of the hot plate kept at constant 
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temperature of 52°C. The latency to lick the paws from the hot plate was measured. To prevent any 
heat injury to pups, a cut-off latency of 30 seconds was applied. 
 
Marble burying  
Mice are placed for thirty minutes in a standard cage empty just filled with 4 cm depth of wood chip 
bedding. After thirty minutes of habituation, 15 marbles are put evenly spaced in the cage. The 
amount of marbles buried is measured after thirty minutes of testing. In this procedure a marble is 
considered buried if 2/3 of the marble is covered with bedding.  
 
Running Wheels 
The cages were equipped with a wheel connected to a system that measures in automatic the 
number of wheel circumvolutions in their home-cage during the 24 hours a day for 20 days. In a 
variant of this test was used a plate placed under the cage and allowing to monitor the motor activity 
of mice. Both of these techniques are totally non-invasive and mice they have access to libitum for 
food and water. Mice were kept under normal conditions of lighting (12:12 LD) for 10 days and in 
constant darkness (DD) for other 10 days to study the rhythms circadian in a free-running condition, 
without any interruption. The animals were kept in conventional cages. Mice were treated with 
vehicle or bumetanide in drinking water (2mg/kg) for the whole period of experiments. We used 
bumetanide treatment in drinking water to allow a constant daily assumption of bumetanide to 
monitor its effect on the circadian rhythms. The circadian period of each mouse was calculated by 
wheel running activity.  
The analyses were performed using the MATLAB (www.mathworks.com). The time devoted to 
ehavioral activity (alpha) during LD and DD conditions, where alpha represents the length of the 
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segment of the daily activity was analyzed and computed with the algorithm described in Leise, 2013 
and Leise et al, 2013. 
 
Statistical analysis  
The statistical analysis was performed using GraphPad Prism 8.3. Where appropriate, the statistical 
significance was assessed using the following parametric test: Student’s t test, two-way ANOVA 
followed by all pairwise Tukey post hoc test. Outliers were excluded only from the final pool of data 
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